Oscar Health (OSCR) 10-K 20 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Jan. 31, 2025	Jun. 28, 2024
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-40154
Entity Registrant Name	Oscar Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1315570
Entity Address, Address Line One	75 Varick Street, 5th Floor
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10013
City Area Code	(646)
Local Phone Number	403-3677
Title of 12(b) Security	Class A Common Stock, $0.00001 par value per share
Trading Symbol	OSCR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 3.1
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024 are incorporated herein by reference in Part III.
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Central Index Key	0001568651
Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		215,053,599
Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		35,514,201

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Philadelphia, Pennsylvania

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue
Premium	$ 8,971,259	$ 5,686,069	$ 3,871,117
Investment income	185,729	155,447	27,594
Services and other	20,576	21,353	64,927
Total revenue	9,177,564	5,862,869	3,963,638
Operating Expenses
Medical	7,332,589	4,642,024	3,280,798
Selling, general, and administrative	1,755,565	1,425,766	1,257,424
Depreciation and amortization	32,145	30,694	15,283
Total operating expenses	9,120,299	6,098,484	4,553,505
Earnings (loss) from operations	57,265	(235,615)	(589,867)
Interest expense	23,734	24,603	22,623
Other expenses (income)	105	7,082	(2,415)
Earnings (loss) before income taxes	33,426	(267,300)	(610,075)
Income tax expense (benefit)	7,305	3,294	(523)
Net income (loss)	26,121	(270,594)	(609,552)
Less: Net income (loss) attributable to noncontrolling interests	689	134	(3,277)
Net income (loss) attributable to Oscar Health, Inc.	$ 25,432	$ (270,728)	$ (606,275)
Earnings (Loss) per Share
Basic (in dollars per share)	$ 0.11	$ (1.22)	$ (2.85)
Diluted (in dollars per share)	$ 0.10	$ (1.22)	$ (2.85)
Weighted Average Common Shares Outstanding
Basic (in shares)	240,386,000	221,655,000	212,475,000
Diluted (in shares)	265,853,000	221,655,000	212,475,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss )	$ 26,121	$ (270,594)	$ (609,552)
Other comprehensive income (loss), net of tax:
Net unrealized gains (losses) on securities available for sale	(3,136)	11,024	(6,044)
Comprehensive income (loss)	22,985	(259,570)	(615,596)
Comprehensive income (loss) attributable to noncontrolling interests	689	134	(3,277)
Comprehensive income (loss) attributable to Oscar Health, Inc.	$ 22,296	$ (259,704)	$ (612,319)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 1,527,186	$ 1,870,315
Short-term investments	624,461	689,833
Premiums and accounts receivable (net of allowance for credit losses of $31,300 and $31,600)	315,891	201,269
Risk adjustment transfer receivable	64,779	51,925
Reinsurance recoverable	291,537	241,194
Other current assets	21,320	6,564
Total current assets	2,845,174	3,061,100
Property, equipment, and capitalized software, net	66,793	61,930
Long-term investments	1,815,254	365,309
Restricted deposits	30,878	29,870
Other assets	82,397	83,271
Total assets	4,840,496	3,601,480
Current Liabilities:
Benefits payable	1,356,730	965,986
Risk adjustment transfer payable	1,558,341	1,056,941
Premium deficiency reserve	0	5,776
Unearned premiums	74,389	65,918
Accounts payable and other liabilities	432,428	273,367
Reinsurance payable	41,346	61,024
Total current liabilities	3,463,234	2,429,012
Long-term debt	299,555	298,777
Other liabilities	61,282	67,574
Total liabilities	3,824,071	2,795,363
Commitments and contingencies (Note 19)
Stockholders' Equity
Treasury stock (315 thousand shares as of December 31, 2024 and 2023)	(2,923)	(2,923)
Additional paid-in capital	3,869,617	3,682,294
Accumulated deficit	(2,851,283)	(2,876,715)
Accumulated other comprehensive income (loss)	(1,827)	1,309
Total Oscar Health, Inc. stockholders’ equity	1,013,586	803,967
Noncontrolling interests	2,839	2,150
Total stockholders’ equity	1,016,425	806,117
Total liabilities and stockholders' equity	4,840,496	3,601,480
Class A
Stockholders' Equity
Common stock	2	2
Class B
Stockholders' Equity
Common stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Premiums and other receivables, allowance for credit loss	$ 31,300	$ 31,600
Treasury stock (in shares)	315	315
Class A
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, authorized (in shares)	825,000	825,000
Common stock, outstanding (in shares)	214,974	193,875
Class B
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, authorized (in shares)	82,500	82,500
Common stock, outstanding (in shares)	35,514	35,514

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Treasury stock	Additional paid-in capital	Accumulated Deficit	Accumulated other comprehensive income (loss)	Noncontrolling interests	Class A Common Stock	Class B Common Stock
Beginning balance (in shares) at Dec. 31, 2021							175,212	35,116
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans (in shares)							5,964	0
Ending balance (in shares) at Dec. 31, 2022							181,176	35,116
Beginning balance at Dec. 31, 2021		$ (2,923)	$ 3,393,533	$ (1,999,712)	$ (3,671)	$ 5,293	$ 2	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans			1,299
Stock-based compensation expense			112,329
Joint venture contribution			1,846
Net income (loss) attributable to Oscar Health, Inc. / Net income (loss) attributable to noncontrolling interests	$ (609,552)			(606,275)		(3,277)
Net unrealized gains (losses) on securities available for sale	(6,044)				(6,044)
Ending balance at Dec. 31, 2022	892,400	(2,923)	3,509,007	(2,605,987)	(9,715)	2,016	$ 2	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans (in shares)							12,699	398
Ending balance (in shares) at Dec. 31, 2023							193,875	35,514
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans			3,956
Stock-based compensation expense			166,841
Joint venture contribution			2,490
Net income (loss) attributable to Oscar Health, Inc. / Net income (loss) attributable to noncontrolling interests	(270,594)			(270,728)		134
Net unrealized gains (losses) on securities available for sale	11,024				11,024
Ending balance at Dec. 31, 2023	806,117	(2,923)	3,682,294	(2,876,715)	1,309	2,150	$ 2	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans (in shares)							21,099	0
Ending balance (in shares) at Dec. 31, 2024							214,974	35,514
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from equity incentive plans			68,388
Stock-based compensation expense			118,935
Joint venture contribution			0
Net income (loss) attributable to Oscar Health, Inc. / Net income (loss) attributable to noncontrolling interests	26,121			25,432		689
Net unrealized gains (losses) on securities available for sale	(3,136)				(3,136)
Ending balance at Dec. 31, 2024	$ 1,016,425	$ (2,923)	$ 3,869,617	$ (2,851,283)	$ (1,827)	$ 2,839	$ 2	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net income (loss )	$ 26,121	$ (270,594)	$ (609,552)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Deferred taxes	(2,338)	58	(165)
Net realized loss (gain) on sale of financial instruments	(23)	70	1,274
Depreciation and amortization expense	32,145	30,694	15,283
Amortization of debt issuance costs	778	778	713
Stock-based compensation expense	109,824	159,683	112,329
Investment amortization (accretion), net of accretion	(26,877)	(29,374)	2,480
Change in provision for credit losses	(300)	28,612	2,988
(Increase) / decrease in:
Premium and other receivables	(114,323)	(13,405)	(81,049)
Risk adjustment transfer receivable	(12,854)	(2,063)	(9,202)
Reinsurance recoverable	(50,343)	651,693	(460,897)
Other assets	(11,547)	11,307	(243)
Increase / (decrease) in:
Benefits payable	390,744	28,258	424,146
Unearned premiums	8,472	(13,080)	3,953
Premium deficiency reserve	(5,776)	1,562	(25,033)
Accounts payable and other liabilities	152,768	(29,180)	57,811
Reinsurance payable	(19,678)	(366,626)	222,418
Risk adjustment transfer payable	501,400	(460,552)	723,095
Net cash (used in) provided by operating activities	978,193	(272,159)	380,349
Cash Flows from Investing Activities:
Purchase of investments	(2,133,510)	(836,982)	(1,192,706)
Sale of investments	25,250	31,857	360,616
Maturity of investments	744,794	1,410,166	633,467
Purchase of property, equipment and capitalized software	(27,897)	(25,577)	(29,012)
Change in restricted deposits	3,929	(2,277)	1,116
Net cash (used in) provided by investing activities	(1,387,434)	577,187	(226,519)
Cash Flows from Financing Activities:
Proceeds from long-term debt	0	0	305,000
Payments of debt issuance costs	0	0	(7,035)
Proceeds from joint venture contribution	0	2,490	1,846
Proceeds from exercise of stock options	68,388	3,956	1,299
Net cash provided by financing activities	68,388	6,446	301,110
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(340,853)	311,474	454,940
Cash, cash equivalents, restricted cash and cash equivalents—beginning of period	1,891,971	1,580,497	1,125,557
Cash, cash equivalents, restricted cash and cash equivalents—end of period	1,551,118	1,891,971	1,580,497
Cash and cash equivalents	1,527,186	1,870,315	1,558,595
Restricted cash and cash equivalents included in restricted deposits	23,932	21,656	21,902
Total cash, cash equivalents and restricted cash and cash equivalents	1,551,118	1,891,971	1,580,497
Supplemental Disclosures:
Interest payments	33,691	23,156	10,079
Income tax payments	$ 674	$ 2,414	$ 1,893

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	ORGANIZATION Oscar Health, Inc., together with its subsidiaries (either individually or collectively referred to as “Oscar” or the “Company”), is a leading healthcare technology company, whose mission is to make a healthier life accessible and affordable for all. The Company’s Class A common stock is traded on the New York Stock Exchange under the symbol “OSCR”. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (“ACA”) and leverages its technology platform to provide services via its +Oscar offering. The Company had partnered with Cigna through the Cigna+Oscar partnership to serve the small group employer market. The Company previously offered Medicare Advantage insurance coverage, but exited the Medicare Advantage market for the 2024 plan year. The Company’s member-first philosophy and innovative approach to care has earned the trust of approximately 1.68 million effectuated members, as of December 31, 2024. Effectuated members are those who are actively enrolled in our plan and have either paid their premium or are within the grace period. Non-Renewal of Cigna+Oscar Partnership and Exit from the Small Group Market On March 26, 2024, the Company notified Cigna Health and Life Insurance Company that it would not renew the Cigna+Oscar Small Group arrangement after the expiration of the initial term on December 31, 2024. The parties continued to offer their Cigna+Oscar Small Group product through December 15, 2024. Following termination of the arrangement on December 31, 2024, the Company will continue to provide transition and run-off services through December 31, 2026 and share proportionally in all premiums and claims for any Cigna+Oscar Small Group plan sold or issued on or before December 15, 2024, in accordance with the terms of the arrangement. Additionally, effective December 15, 2024, Oscar no longer offered small group products in any market.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Consolidated Financial Statements include the accounts of the Company, all of the controlled subsidiaries and variable interest entities of which the Company is the primary beneficiary. Noncontrolling interest consists of equity that is not attributable directly or indirectly to the Company. All material intercompany transactions have been eliminated in consolidation. Balances (except per share data) are presented in U.S. dollars and rounded, as indicated. In order to preserve the mathematical accuracy of the underlying calculations, immaterial footing differences may occur between the sum of individual balances and the total balances presented. Reclassification With the commencement of the current fiscal year, the Company has made certain reclassifications to the income statement to provide more transparency into the Company’s streams of revenue and to increase comparability with peers. This reclassification has been applied retrospectively, and comparative figures for prior periods have been adjusted accordingly within the accompanying Consolidated Financial Statements. The reclassification does not affect the Company’s Net income. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements. Significant estimates inherent in the preparation of the accompanying audited Consolidated Financial Statements include healthcare costs incurred but not yet reported (“IBNR”) and risk adjustment transfers. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ materially from these estimates. Segment Information Oscar operates as one reportable segment to sell insurance to its members through the federal and state-run healthcare exchanges formed in conjunction with the ACA and leverages its technology platform to provide services via its +Oscar Offering. The Company determined that our Chief Executive Officer is the chief operating decision maker (“CODM”) who regularly reviews financial information and other key performance indicators on a consolidated basis, for the purposes of allocating resources and evaluating financial performance. Factors used in determining the reportable segment include the nature of operating activities, the Company’s organizational and reporting structure, and the type of information presented to the Company’s CODM to allocate resources and evaluate financial performance. Revenue Premium Premium revenue includes direct policy premiums collected directly from members and subsidies received from the Centers for Medicare & Medicaid Services (“CMS”) as part of the Advanced Premium Tax Credit (“APTC”) and Medicare Advantage programs, along with assumed premiums from the Company's reinsurance agreement. Premium revenue is adjusted for the estimated impact of the risk adjustment program required by CMS. Total premiums earned is net of ceded premium from excess of loss (“XOL”) and run-off quota share reinsurance contracts accounted for under reinsurance accounting. The Company receives a fixed premium per member per month and recognizes premium revenue during the period in which it is obligated to provide services to its members. For direct policy premiums received from CMS, revenue is recorded based on membership and eligibility criteria provided by CMS and is subject to monthly adjustment by CMS. The Company conducts business through the federal and state-run healthcare exchanges formed in conjunction with ACA and is therefore subject to certain risk stabilization programs and fees established by ACA, such as: Risk Adjustment and Minimum Medical Loss Ratio (“MLR”) requirements. The ACA risk adjustment program is administered federally by CMS. Under this program, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores relative to the estimated market average risk score, when applied to the statewide average premium, will have a risk adjustment payable into the pool. Inversely, plans with higher than average risk scores relative to the estimated market average risk score, when applied to the statewide average premium, will have a risk adjustment receivable from the pool. Management develops its membership risk scores for the risk adjustment payable using actuarial methodologies and assumptions and by analyzing member data, including demographic and projections of claims data expected to be submitted by the Company to CMS for settlement. Generally, the estimated market average risk score and statewide average premium are obtained from third party surveys of other insurance plans. There is judgment in estimating the Company’s membership risk scores and the estimated market average risk scores. Management refines its estimate as new information becomes available and the final report on actual market risk scores is received from CMS in June of the following year. In addition, CMS and the Office of Inspector General for Health and Human Services (“HHS”) perform risk adjustment data validation (“RADV”) audits of health insurance plans to validate the coding practices of and supporting documentation maintained by healthcare providers, and such audits have in the past and may in the future result in adjustments to risk transfer payments. The ACA established a minimum MLR ratio that requires insurers to pay rebates to customers when MLR is below established thresholds. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue for purposes of calculating the required minimum MLR. The Company records estimated MLR rebates as an adjustment to premium revenue. Services and Other The Company earns revenue as part of services performed via the +Oscar platform. Services revenue is recognized in the period the contractual performance obligations are satisfied and measured in an amount that reflects the consideration the Company expects to be entitled to in exchange for performing the services. The timing of the Company's revenue recognition may differ from the timing of payment by customers. A receivable is recorded to Premiums and accounts receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, deferred revenue is recorded to Accounts payable and other liabilities when payment is received before the performance obligations are satisfied. Other revenue includes primarily sublease income. Reinsurance The Company participates in reinsurance agreements to limit risk and meet its capital requirements. The Company currently enters into two different types of arrangements: quota share reinsurance contracts that do not meet risk transfer requirements and XOL reinsurance contracts. The quota share reinsurance contracts are accounted for under the deposit accounting method. Under deposit accounting, the contract is recorded as a financing, with no impact to premium revenue or medical expenses. In XOL reinsurance, the reinsurer agrees to assume all or a portion of the ceding company’s losses in excess of a specified amount. Under XOL reinsurance, the premium payable to the reinsurer is negotiated by the parties based on losses on an individual member in a given calendar year and their assessment of the amount of risk being ceded to the reinsurer. Premiums under XOL reinsurance agreements are based on enrollment calculated on a per member per month basis. The XOL contracts are accounted for under reinsurance accounting and, as such, the Company records premium paid to the reinsurer as a reduction to premium revenue. In the case of federal and state-run reinsurance programs, no reinsurance premiums are paid. Expected reimbursement from the reinsurer for claims incurred are recorded as a reduction to medical expenses. Reinsurance contracts are renewed periodically and we review them in advance of the contract’s expiration to negotiate terms for new reinsurance contracts. During each renewal cycle, there are a number of factors considered when determining reinsurance coverage, including (1) plans to change the underlying insurance coverage offered by the Company, (2) trends in loss activity, (3) the level of the insurance subsidiaries' capital and surplus, (4) changes in the Company's risk appetite, and (5) the cost and availability of reinsurance coverage. In addition to ceded reinsurance, an Oscar health insurance subsidiary partially reinsures the Cigna+Oscar small group offering through a quota share reinsurance arrangement. The Company records assumed premiums and assumed claims. Refer to Note 11 - Reinsurance for more information. Premium Deficiency Reserve Premium deficiency reserve (“PDR”) liabilities are established when it is probable that expected future claims and maintenance expenses will exceed future premium and reinsurance recoveries based on existing insurance contract terms including consideration of net investment income. For purposes of determining premium deficiency reserves, contracts are grouped consistent with the Company’s method of acquiring, servicing, and measuring the profitability of such contracts, which is generally on a line of business basis. The Company records PDR expenses within Selling, general, and administrative expenses on the Consolidated Statements of Operations. Cash and Cash Equivalents Cash and cash equivalents consists of highly liquid investments with original maturities of three months or less. Restricted Deposits The Company defines restricted deposits as restricted cash, cash equivalents, and investments maintained on deposit or pledged primarily to various state agencies in connection with its insurance licensure. Statutory regulations require these amounts to remain on deposit indefinitely; therefore, the Company classifies these restricted deposits as long-term regardless of the contractual maturity date of the securities held. Restricted cash equivalents and investments are recorded at fair value. Investments The majority of the Company's investments are classified as available-for-sale and are carried at fair value. Short-term investments include securities with maturities between three months and one year. Long-term investments include securities with maturities greater than one year. Under the Company's current expected credit loss (“CECL”) model, the Company evaluates its available-for-sale debt investments for impairment by monitoring the difference between the carrying value and fair value of a security and whether declines in fair value are credit-related. If a security is in an unrealized loss position and the Company has the intent to sell, or it is more likely than not that the security will be sold before recovery of its amortized cost basis, the decline in fair value is recognized as a loss on the income statement. For securities in an unrealized loss position that the Company does not intend to sell, the Company performs an evaluation to determine what portion of the unrealized losses are credit-related; this portion is recognized on the income statement as an allowance for credit losses. The remaining non-credit-related portion of the decline in fair value is recognized as an unrealized loss in Accumulated other comprehensive income (loss). Allowance for Credit Losses Premium and other receivables primarily includes insurance premiums due from CMS and members, pharmaceutical rebates, and other claims-related provider receivables and are reported net of any allowance for credit losses. Receivable balances are also recorded related to the Company's risk adjustment program, reinsurance program, and value-based care arrangements. An allowance for credit losses is generally calculated based on historical collection experience, the counterparty's creditworthiness, and consideration of current and future economic events. As part of value-based care arrangements, the Company entered into risk sharing arrangements with certain of its providers. The intention of these agreements is to align incentives with providers who desire to share accountability for the quality and costs of managing a population of Oscar’s members. If medical expenses exceed agreed upon population-specify target MLR, the provider reimburses the Company an agreed upon portion of the excess expenses creating a risk share receivable due to the Company. The Company recorded risk sharing receivables on a gross basis on the Consolidated Balance Sheet. The Company evaluated expected losses on risk sharing receivables and recorded and adjusted the resulting expected losses to the allowance for credit losses based on the counterparty’s financial health and creditworthiness and any significant changes in the healthcare environment. The Company writes off the receivable balance when it is determined to be uncollectible. The Company has presented the rollforward related to its allowance for credit losses on our risk sharing receivables below: For the year ended December 31, (in thousands) 2024 2023 Beginning balance $ 31,600 $ 2,988 Provision for credit losses (300) 28,612 Ending balance $ 31,300 $ 31,600 Policy Acquisition Costs Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include broker commissions, costs of policy issuance and underwriting, and other costs incurred to acquire new business or renew existing business. Policy acquisition costs, other than broker bonus commissions, are expensed in the period incurred. Broker bonuses are capitalized and amortized over the policy term. The Company's short-duration policies typically have a one-year term and may be canceled by the member upon 30 days' notice. Income Taxes Income taxes are accounted for under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the bases of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be realized. Benefits Payable Benefits payable consists of liabilities for both IBNR and reported but not yet processed through the Company's systems that are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. IBNR is an actuarial estimate, determined by employing actuarial methods, that is based on claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors. For low severity incurred but not paid claims, for the months prior to the most recent two months, the Company typically uses the completion factor development method. This methodology is a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project the Company's best estimate of claim liabilities. Under this method, historical paid claims data is formatted into claim triangles, which compare claim incurred dates to the dates of claim payments. This information is analyzed to create historical completion factors that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims. A seriatim methodology is utilized for high dollar claims which is supplemented by case management data supplied by medical and claims operations areas. For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are primarily based on forecasted per member per month low dollar claims projections developed from the Company’s historical experience and adjusted for emerging experience data in the preceding months, which may include adjustments for known changes in estimates of recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality. Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes. These adjustments are made by the Company's actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing the Company's best estimate of reserves include changes in utilization levels, unit costs, member cost sharing, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, and claim submission patterns. The Company regularly reviews and sets assumptions regarding cost trends and utilization when initially establishing claim liabilities. The Company continually monitors and adjusts the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that the Company's assumptions regarding cost trends and utilization are materially different from actual results, the Company's income statement and financial position could be impacted in future periods. Adjustments of prior year estimates may result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of healthcare costs, adjustments to claim liabilities occur each period and are sometimes significant as compared to the net income recorded in that period. Prior period development is recognized immediately upon the actuary’s judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable. Disputed Claim Reserves The Company also records, as part of benefits payable, an estimate of the ultimate liability for actual and potential claims disputes by providers based on an analysis of historical per member per month (“PMPM”) dispute experience supplemented with current information on reported disputes. Since these liabilities are part of the overall claim reserve, they are proportionally ceded under the Company's reinsurance agreements for historical policy years with contracts in force. The disputed claim reserves included as part of the benefits payable balance was approximately $183.7 million and $241.1 million as of December 31, 2024 and 2023, respectively. Unallocated Claims Adjustment Expenses Claims adjustment expenses (“CAE”) are costs incurred or expected to be incurred in connection with the adjustment and recording of health claims not subject to reinsurance. Such expenses include, but are not limited to, case management, utilization review, and quality assurance and are intended to reduce the number of health services provided or the cost of such services. CAE is included in other insurance costs and the related CAE payable is included in accounts payable and accrued liabilities. Property, Equipment, and Capitalized Software Property, equipment, and capitalized software are reported at cost less accumulated depreciation. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the related assets, which range from two three Leases The Company leases office space under operating leases expiring on various dates through 2032. On the lease commencement date, a right-of-use (“ROU”) asset and lease liability are recognized as Other assets and Other Liabilities on the Consolidated Balance Sheets based on the present value of the future minimum lease payments over the lease term. Since the Company's lease agreements do not provide an implicit rate, an incremental borrowing rate, based on the information available at commencement date, is used to determine the present value of future payments. The calculation of the ROU asset is based on the lease liability, and includes any lease payments made, and excludes lease incentives and initial direct costs incurred. The Company determines if an arrangement is a lease or contains a lease at inception of the arrangement based on the terms and conditions in the contract. Options to extend or terminate a lease at the Company's discretion are factored into the calculation of the lease liabilities and ROU assets only if the Company is reasonably certain it will exercise those options. Short-term leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease expense for the Company's operating leases is calculated on a straight-line basis over the lease term.within Selling, general, and administrative expenses on the Consolidated Statements of Operations. Lease and non-lease components are accounted for as a single lease component for all asset classes. Earnings Per Share Earnings (loss) per share (“EPS”) is calculated using the two-class method, which is an earnings allocation model that treats participating securities as having rights to earnings that otherwise would have been available to common stockholders. Under the two-class method, earnings for the period are required to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. For EPS computation purposes, the Company's Class A and Class B common stock are considered one single class of common stock because both classes have the same dividend and liquidation rights. Refer to Note 3 - Earnings (Loss) Per Share for a description of our basic and diluted EPS calculations. Variable Interest Entities The Company enters arrangements with various entities that are deemed to be variable interest entities (“VIE”). A VIE is an entity that either (1) has equity investors that lack certain essential characteristics of a controlling financial interest (including the ability to control activities of the entity, the obligation to absorb the entity’s expected losses, and the right to receive the entity’s expected residual returns) or (2) lacks sufficient equity to finance its own activities without financial support provided by other entities, which in turn would be expected to absorb at least some of the expected losses of the VIE. The Company is deemed a primary beneficiary of a VIE if it has (1) the power to direct the activities of the VIE that most significantly impact the economic performance of the VIE and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could be potentially significant to the VIE. If both conditions are present, the Company is required to consolidate the VIE into its financial results. Accounting Pronouncements - Recently Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which requires, for each reportable segment, disclosure of significant segment expense categories, other segment items, enhanced interim disclosures of certain segment-related disclosures that previously were only required annually, and other disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 and provided additional segment footnote disclosures in the Company's annual Consolidated Financial Statements for the year ending December 31, 2024. In addition, the Company provided enhanced disclosures regarding the measure of profit or loss reviewed by the CODM as well as enhanced expense disclosures. Accounting Pronouncements - Not Yet Adopted In December 2023, the FASB issued Accounting Standards Update No. 2023-09 ("ASU 2023-09"), Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which is intended to improve the transparency of income tax disclosures by requiring greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid and other amendments to improve the effectiveness of income tax disclosures. This guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. ASU 2023-09 applies on a prospective basis; however, retrospective application in all prior periods presented is permitted. While the standard will require additional disclosures related to the Company’s income taxes, the standard is not expected to have any material impact on the Company’s consolidated operating results, financial condition, or cash flows. The Company is currently evaluating the impact of the adoption of this guidance on the related disclosures before it becomes effective for the Company’s 2025 annual financial statements. In November 2024, the FASB issued Accounting Standards Update No. 2024-03 ("ASU 2024-03"), Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosures in the notes to financial statements, disaggregating specific expense categories for relevant income statement captions and additional disclosures of the Company's total amount of selling expenses. This guidance is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Consolidated Financial Statements.

REVENUE RECOGNITION

REVENUE RECOGNITION	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION Premiums earned The composition of Premium revenue on the Consolidated Statement of Operations is as follows: Year Ended December 31, (in thousands) 2024 2023 2022 Direct policy premiums $ 10,292,125 $ 6,418,872 $ 6,704,330 Assumed premiums 219,572 228,786 138,109 Risk adjustment transfers (1,526,448) (950,680) (1,507,919) Reinsurance premiums ceded (13,990) (10,909) (1,463,403) Premium $ 8,971,259 $ 5,686,069 $ 3,871,117 The direct policy premiums earned from CMS as part of APTC and Medicare Advantage for the years ended December 31, 2024, 2023, and 2022 were $9,512.3 million, $5,521.9 million, and $5,730.1 million, respectively. The Company's insurance subsidiaries prepare financial statements in accordance with Statutory Accounting Principles ("SAP") prescribed or permitted by the insurance departments of their states of domicile. SAP are focused on the solvency of insurance companies and are designed to ensure that insurers maintain sufficient capital and surplus to meet their insurance-related obligations. The Company's insurance subsidiaries are regulated by the state insurance departments of the states in which they are domiciled. Statutory regulations include the establishment of minimum levels of statutory capital to be maintained by insurance subsidiaries and restrictions on dividend payments and other distributions made by the insurance subsidiaries to the parent company. Minimum statutory capital requirements differ by state and are based on minimum risk-based capital ("RBC") requirements developed by the National Association of Insurance Commissioners ("NAIC"). As of December 31, 2024, the Company's insurance subsidiaries are estimated to have an aggregate statutory capital and surplus of approximately $1,242.7 million. As of December 31, 2023, the Company’s insurance subsidiaries had an aggregate statutory capital and surplus of $800.6 million. Individually, each of the Company's insurance subsidiaries is projected to exceed the minimum required statutory capital and surplus and RBC minimum requirements.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic EPS is computed by dividing net income (loss) attributable to Oscar Health, Inc. for the period by the weighted-average shares of common stock outstanding during the period. In periods when the Company is in a net loss position, potentially dilutive securities are excluded from the computation of diluted EPS because their inclusion would have an anti-dilutive effect. Thus, basic EPS is the same as diluted EPS. During periods of net income, diluted EPS is computed by dividing Net income attributable to Oscar Health, Inc. by the sum of the basic weighted-average shares of common stock outstanding and any dilutive potential common stock outstanding during the period, using the treasury stock method and the if-converted method for convertible senior notes, as described in Note 9 - Debt. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock units and, performance-based restricted stock units. For the year ended December 31, 2024, the impact of convertible senior notes was anti-dilutive on dilutive EPS, and therefore excluded from the computation below. The computation for basic and diluted EPS is as follows: Year Ended December 31, (in thousands, except per share data) 2024 2023 2022 Numerator : Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) Effect of convertible senior notes — — — Net income (loss) available to Oscar Health, Inc. common shareholders $ 25,432 $ (270,728) $ (606,275) Denominator : Weighted average shares of common stock outstanding, basic and diluted 240,386 221,655 212,475 Common stock equivalents 25,467 — — Effect of convertible senior notes — — — Weighted average shares of common stock and potential dilutive common shares outstanding 265,853 221,655 212,475 Net Earnings (Loss) per Share Basic $ 0.11 $ (1.22) $ (2.85) Diluted $ 0.10 $ (1.22) $ (2.85) The following potential common shares were excluded from the computation of diluted EPS because including them would have had an anti-dilutive effect: Year Ended December 31, (in thousands) 2024 2023 2022 Stock options to purchase common stock $ 1,249 $ 26,378 $ 28,729 Restricted stock units 346 21,723 17,596 Performance-based restricted stock units — 9,305 8,465 Shares underlying convertible notes (Note 9) 36,652 36,652 36,652 Total $ 38,247 $ 94,058 $ 91,442

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS Net investment income was attributable to the following: Year Ended December 31, (in thousands) 2024 2023 2022 Fixed maturity securities $ 82,085 $ 59,965 $ 10,713 Cash equivalents 98,618 90,152 22,121 Other (1) 5,823 6,148 (4,202) Investment income 186,526 156,265 28,632 Investment expense (797) (818) (1,038) Net investment income $ 185,729 $ 155,447 $ 27,594 (1) Represents the net interest earned (paid) on funds withheld. For the years ended December 31, 2024 and 2023, the Company recorded accrued investment income of $19.8 million and $6.6 million, respectively. The following tables provide summaries of the Company's investments by major security type as of December 31, 2024 and 2023: December 31, 2024 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. treasury and agency securities $ 1,946,759 $ 6,631 $ (9,028) $ 1,944,362 Corporate notes 463,261 1,346 (799) 463,808 Certificate of deposit 29,136 — — 29,136 Other (1) 2,409 — — 2,409 Total $ 2,441,565 $ 7,977 $ (9,827) $ 2,439,715 (1) Includes equity securities without a readily determinable market value. December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. treasury and agency securities $ 802,288 $ 1,689 $ (1,062) $ 802,915 Corporate notes 234,908 854 (198) 235,564 Certificate of deposit 16,663 — — 16,663 Total $ 1,053,859 $ 2,543 $ (1,260) $ 1,055,142 The following tables present the estimated fair value and gross unrealized losses of fixed maturity securities in a gross unrealized loss position, by the length of time in which the securities have continuously been in that position, as of December 31, 2024 and 2023: December 31, 2024 Less than 12 Months 12 Months or Longer (in thousands, except no. of securities) Number of Securities Fair Value Gross Number of Securities Fair Value Gross U.S. treasury and agency securities 191 $ 730,938 $ (9,003) 6 $ 47,748 $ (25) Corporate notes 110 146,349 (799) — — — Total 301 $ 877,287 $ (9,802) 6 $ 47,748 $ (25) December 31, 2023 Less than 12 Months 12 Months or Longer (in thousands, except no. of securities) Number of Securities Fair Value Gross Number of Securities Fair Value Gross U.S. treasury and agency securities 69 $ 480,312 $ (995) 4 $ 24,551 $ (67) Corporate notes 64 79,024 (166) 19 5,545 (32) Total 133 $ 559,336 $ (1,161) 23 $ 30,096 $ (99) The Company monitors available-for-sale debt securities for credit losses and recognizes an allowance for credit losses when factors indicate a decline in the fair value of a security is credit-related. Certain investments may experience a decline in fair value due to changes in market interest rates, changes in general economic conditions, or a deterioration in the credit worthiness of a security's issuer. For securities in an unrealized loss position that the Company does not intend to sell, the Company has assessed the gross unrealized losses during the period and determined an allowance for credit losses is not necessary because the declines in fair value are believed to be due to market fluctuations and not due to credit-related events. The amortized cost and fair value of the Company's fixed maturity as of December 31, 2024 and 2023 by contractual maturity are shown below. Actual maturities of these securities could differ from their contractual maturities because issuers may have the right to call or prepay obligations, with or without penalties. December 31, 2024 December 31, 2023 (in thousands) Amortized Cost Fair Value Amortized Cost Fair Value Due in one year or less $ 623,465 $ 624,461 $ 690,694 $ 689,833 Due after one year through five years 1,815,691 1,812,845 363,165 365,309 Total $ 2,439,156 $ 2,437,306 $ 1,053,859 $ 1,055,142

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value represents the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. The Company's financial assets and liabilities measured at fair value on a recurring basis are categorized into a three-level fair value hierarchy based on the priority of the inputs used in the fair value valuation technique. The levels of the fair value hierarchy are as follows: • Level 1 : Inputs utilize quoted (unadjusted) prices in active markets for identical assets or liabilities. • Level 2 : Inputs utilize quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations in which all significant inputs are observable in active markets. • Level 3 : Inputs utilized are unobservable but significant to the fair value measurement for the asset or liability. The unobservable inputs are used to measure fair value to the extent relevant observable inputs are not available. The unobservable inputs typically reflect management’s own estimates about the assumptions a market participant would use in pricing the asset or liability. The following tables summarize fair value measurements by level for assets and liabilities measured at fair value on a recurring basis: December 31, 2024 (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurement Assets Cash equivalents $ 95,331 $ — $ — $ 95,331 Investments U.S. treasury and agency securities $ — $ 1,944,362 $ — $ 1,944,362 Corporate notes — 463,808 — 463,808 Certificate of deposit — 29,136 — 29,136 Restricted investments Certificates of deposit — — — — U.S. treasury securities — 6,946 — 6,946 Total assets $ 95,331 $ 2,444,252 $ — $ 2,539,583 December 31, 2023 (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurement Assets Cash equivalents $ 434,330 $ — $ — $ 434,330 Investments U.S. treasury and agency securities $ — $ 802,915 $ — $ 802,915 Corporate notes — 235,564 — 235,564 Certificate of deposit — 16,663 — 16,663 Restricted investments Certificate of deposit — 2,478 — 2,478 U.S. treasury securities — 5,736 — 5,736 Total assets $ 434,330 $ 1,063,356 $ — $ 1,497,686

RESTRICTED CASH AND RESTRICTED

RESTRICTED CASH AND RESTRICTED DEPOSITS	12 Months Ended
	Dec. 31, 2024
Cash and Cash Equivalents [Abstract]
RESTRICTED CASH AND RESTRICTED DEPOSITS	RESTRICTED CASH AND RESTRICTED DEPOSITS The Company maintains cash, cash equivalents and investments on deposit or pledged primarily to various state agencies in connection with its insurance licensure. The restricted cash and cash equivalents and restricted investments presented below are included in “restricted deposits” in the accompanying Consolidated Balance Sheets. As of December 31, (in thousands) 2024 2023 Restricted cash and cash equivalents $ 23,932 $ 21,656 Restricted investments 6,946 8,214 Restricted deposits $ 30,878 $ 29,870

BENEFITS PAYABLE

BENEFITS PAYABLE	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
BENEFITS PAYABLE	BENEFITS PAYABLE Reserves for medical claims expenses are estimated using actuarial assumptions and recorded as a Benefits payable liability on the Consolidated Balance Sheets. The assumptions for the estimates and for establishing the resulting liability are reviewed, and any adjustments to reserves are reflected in the Consolidated Statement of Operations in the period in which the estimates are updated. The following table provides a rollforward of the Company’s beginning and ending Benefits payable and CAE payable balances for the years ended December 31, 2024, 2023, and 2022: Year Ended December 31, 2024 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 965,986 $ 13,192 $ 979,178 Less: Reinsurance recoverable 57,111 — 57,111 Benefits payable, beginning of the period, net $ 908,875 $ 13,192 $ 922,067 Claims incurred and CAE Current year $ 7,497,259 $ 108,492 $ 7,605,751 Prior years (164,670) — (164,670) Total claims incurred and CAE, net $ 7,332,589 $ 108,492 $ 7,441,081 Claims paid and CAE Current year $ 6,349,624 $ 92,758 $ 6,442,382 Prior years 593,745 10,685 604,430 Total claims and CAE paid, net $ 6,943,369 $ 103,443 $ 7,046,812 Benefits and CAE payable, end of period, net $ 1,298,095 $ 18,241 $ 1,316,336 Add: Reinsurance recoverable 58,635 — 58,635 Benefits and CAE payable, end of period $ 1,356,730 $ 18,241 $ 1,374,971 Year Ended December 31, 2023 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 937,727 $ 12,712 $ 950,439 Less: Reinsurance recoverable 277,944 — 277,944 Benefits payable, beginning of the period, net $ 659,783 $ 12,712 $ 672,495 Claims incurred and CAE Current year $ 4,622,263 $ 105,565 $ 4,727,828 Prior years 19,761 — 19,761 Total claims incurred and CAE, net $ 4,642,024 $ 105,565 $ 4,747,589 Claims paid and CAE Current year $ 3,840,009 $ 94,807 $ 3,934,816 Prior years 552,923 10,278 563,201 Total claims and CAE paid, net $ 4,392,932 $ 105,085 $ 4,498,017 Benefits and CAE payable, end of period, net $ 908,875 $ 13,192 $ 922,067 Add: Reinsurance recoverable 57,111 — 57,111 Benefits and CAE payable, end of period $ 965,986 $ 13,192 $ 979,178 Year Ended December 31, 2022 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 513,582 $ 9,101 $ 522,683 Less: Reinsurance recoverable 159,180 — 159,180 Benefits payable, beginning of the period, net $ 354,402 $ 9,101 $ 363,503 Claims incurred and CAE Current year $ 3,279,460 $ 117,541 $ 3,397,001 Prior years 1,338 — 1,338 Total claims incurred and CAE, net $ 3,280,798 $ 117,541 $ 3,398,339 Claims paid and CAE Current year $ 2,726,912 $ 106,871 $ 2,833,783 Prior years 248,505 7,059 255,564 Total claims and CAE paid, net $ 2,975,417 $ 113,930 $ 3,089,347 Benefits and CAE payable, end of period, net $ 659,783 $ 12,712 $ 672,495 Add: Reinsurance recoverable 277,944 — 277,944 Benefits and CAE payable, end of period $ 937,727 $ 12,712 $ 950,439 Amounts incurred related to prior periods vary from previously estimated liabilities as more claim information becomes available and claims are ultimately settled. The favorable development recognized in the year ended December 31, 2024 resulted primarily from lower than expected paid claims. The following tables provide information about incurred, paid healthcare claims development, unpaid claims liability, and cumulative claims frequency. The claims development information for all periods preceding the most recent reporting period is considered required unaudited supplementary information. For claims frequency information summarized below, a claim is defined as the financial settlement of a single medical event in which remuneration was paid to the servicing provider. Total IBNR plus expected development on reported claims represents estimates for claims incurred but not reported and development on reported claims. The Company estimates its liability using actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. These actuarial methods consider factors such as historical data for payment patterns, cost trends, product mix, seasonality, utilization of healthcare services, and other relevant factors. Incurred Healthcare Claims Net of Reinsurance Year Ended December 31, IBNR Cumulative number of reported claims (Unaudited) (Unaudited) (in thousands) 2022 2023 2024 Date of Service 2022 $ 3,279,461 $ 3,314,332 $ 3,310,967 $ 31,889 12,725 2023 4,622,263 4,469,672 95,688 11,526 2024 7,497,259 1,147,635 17,917 Total claims incurred $ 15,277,898 Cumulative Paid Healthcare Claims Net of Reinsurance Year Ended December 31, (Unaudited) (Unaudited) (in thousands) 2022 2023 2024 Date of Service 2022 $ 2,726,912 $ 3,223,917 $ 3,279,078 2023 3,840,009 4,373,984 2024 6,349,624 Total payment of incurred claims 14,002,686 All outstanding liabilities prior to 2022, net of reinsurance 22,883 Total benefits payable, net of reinsurance $ 1,298,095 The following table reconciles total outstanding liabilities, net of reinsurance to Benefits payable in the Consolidated Balance Sheet: As of December 31, (in thousands) 2024 2023 Short-duration healthcare costs payable, net of reinsurance $ 1,298,095 $ 908,875 Reinsurance recoverables 58,635 57,111 Total benefits payable $ 1,356,730 $ 965,986

DEBT

DEBT	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
DEBT	DEBT Convertible Senior Notes In February 2022, the Company issued $305.0 million in aggregate principal amount of convertible senior notes due 2031 (the “2031 Notes”) in a private placement to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital, LionTree Investment Management, LLC and Tenere Capital LLC (the “Initial Purchasers”). In connection with the issuance of the 2031 Notes, on January 27, 2022, the Company entered into an investment agreement with the Initial Purchasers (the “Investment Agreement”) and on February 3, 2022, the Company entered into an indenture with U.S. Bank, as Trustee (the “Indenture”). The 2031 Notes bear interest at a rate of 7.25% per annum, payable in cash, semi-annually in arrears on June 30 and December 31 of each year, commencing on June 30, 2022. The 2031 Notes will mature on December 31, 2031, subject to earlier repurchase, redemption, or conversion. The 2031 Notes are the Company's senior, unsecured obligations and are (i) equal in right of payment with the Company's existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company's existing and future indebtedness that is expressly subordinated to the 2031 Notes; (iii) effectively subordinated to the Company's existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company's subsidiaries. The 2031 Notes are convertible into the Company's Class A common stock at initial conversion rates of 120.1721 per $1,000 principal amount (equivalent to an initial conversion price of approximately $8.32 per share of Class A common stock), subject to customary adjustments upon the occurrence of certain events. In addition, upon the occurrence of a make-whole fundamental change, as defined in the Indenture governing the 2031 Notes (the "Indenture"), the Company will, in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its 2031 Notes in connection with such make-whole fundamental change. The 2031 Notes may be converted at the option of the holders, on or after August 31, 2031, if the Company calls the 2031 Notes for redemption, upon the satisfaction of a Class A common stock sale price or 2031 Note trading price condition, or upon certain corporate events. Upon conversion, the 2031 Notes will be settled, at the Company's election, in shares of Class A common stock, cash, or a combination of cash and shares of Class A common stock, unless an Initial Purchaser of the 2031 Notes elects to receive the consideration due upon conversion solely in shares of Class A common stock pursuant to the terms of the Investment Agreement. During the quarterly period ended December 31, 2024, the Class A stock sale price condition was satisfied when the last reported sales price per share of the Company’s Class A common stock was greater than 130% of the conversion price of $8.32 per share for each of at least twenty (20) trading days during the period of thirty (30) consecutive trading days ending on, and including, the last trading day of the quarter. As a result, the 2031 Notes are convertible during the first quarter of 2025 at the option of the holders. As of the date of this Annual Report on Form 10-K, the 2031 Notes have not been converted. Upon the occurrence of a fundamental change (as defined in the Indenture), holders of the 2031 Notes have the right to require the Company to repurchase all or some of their 2031 Notes for cash, subject to certain conditions. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. Additionally, the initial purchasers of the 2031 Notes have the right to require the Company to repurchase all of their Notes for cash, on each of June 30, 2027, June 30, 2028, June 30, 2029 and June 30, 2030, subject to certain notice requirements. The Company may not redeem the 2031 Notes prior to December 31, 2026. The Company may redeem all, but not less than all, of the 2031 Notes, at the Company's option, on or after December 31, 2026 and on or before the 35th scheduled trading day immediately preceding the maturity date, for a cash purchase price equal to the redemption price, but only if the last reported sale price per share of Class A common stock exceeds 200% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date on which the Company sends the redemption notice for such redemption. The redemption price will be a cash amount equal to the principal amount of the 2031 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. Notwithstanding the foregoing, if the Company calls any of the 2031 Notes for redemption the Initial Purchasers have the right to convert the 2031 Notes and to elect to receive the consideration due upon conversion solely in shares of Class A common stock pursuant to the terms of the Investment Agreement. The 2031 Notes include customary provisions relating to the occurrence of “Events of Default” (as defined in the Indenture), as well as customary covenants for convertible notes of this type, including restrictions on the Company's ability to refinance the Company's indebtedness and incur additional indebtedness. As of December 31, 2024, the net carrying amount of the 2031 Notes was $299.6 million, with unamortized debt discount and issuance costs of $5.4 million. The Company classified the fair value of the 2031 Notes as a level 3 measurement due to the lack of observable market data over fair value inputs such as our stock price volatility over the term of the 2031 Notes and the Company's cost of debt. The estimated fair value of the 2031 Notes as of December 31, 2024 was $539.8 million. The following table presents the interest expense indicating an effective interest rate of 7.61% over the term of the 2031 Notes: December 31, (in thousands) 2024 2023 Coupon interest expense $ 21,928 $ 22,112 Amortization of debt discount and issuance costs 778 778 Total interest expense $ 22,706 $ 22,890 Revolving Credit Facility On December 28, 2023, the Company entered into a third amendment to its senior secured credit agreement (the “Third Amendment”), with Wells Fargo Bank, National Association, as lender and administrative agent, and certain other lenders party thereto from time to time (collectively, the “Lenders”), and Oscar Management Corporation, as a subsidiary guarantor, which amended the senior secured credit agreement, dated as of February 21, 2021 (as amended by the First Amendment to Credit Agreement, dated as of January 27, 2022, and as further amended by the Second Amendment to Credit Agreement, dated as of July 21, 2023, the “Credit Agreement” and as amended by the Third Amendment, the “Amended Credit Agreement”). The Amended Credit Agreement provides for a revolving loan credit facility (the “Revolving Credit Facility”) in the aggregate principal amount of $115.0 million, with proceeds to be used for general corporate purposes of the Company. Under the terms of the Revolving Credit Facility, borrowings under the Revolving Credit Facility bear interest at a rate equal to, at the Company's option, either (a) an adjusted term secured overnight financing rate ("SOFR"), plus an applicable margin of 4.50% (SOFR is calculated based on one-, three- or six-month SOFR, or such other period as agreed by all relevant Lenders, which is determined by reference to the SOFR administrator’s website, but not less than 1.00%), or (b) a rate per annum equal to the Alternate Base Rate, as defined in the Revolving Credit Facility, plus the applicable margin of 3.50% (the Alternate Base Rate is equal to the highest of (i) the prime rate, (ii) the federal funds effective rate plus 0.50%, and (iii) SOFR based on a one-month interest period, plus 1.00%). The Revolving Credit Facility also includes a commitment fee of 0.50% for available but undrawn amounts and other administrative fees that are payable quarterly. The Revolving Credit Facility is guaranteed by Oscar Management Corporation, each wholly owned subsidiary of the Company, and all of the Company's future direct and indirect subsidiaries (in each case subject to certain permitted exceptions, including exceptions for guarantees (i) that would require material governmental consents or (ii) in respect of joint ventures) (the "Guarantors"). Oscar Management Corporation is currently the only Guarantor. The Revolving Credit Facility is secured by substantially all of the Company’s and the Guarantors' assets (subject to certain exceptions). The Revolving Credit Facility is available for the Company to borrow under until December 28, 2025, provided the Company is in compliance with the restrictive and financial covenants contained therein, including financial covenants to maintain minimum thresholds related to direct policy premiums, consolidated Adjusted EBITDA (as defined in the Revolving Credit Facility), and liquidity, as well as a maximum medical loss ratio. The Company is permitted to increase commitments under the Revolving Credit Facility by an aggregate amount not to exceed $50.0 million, subject to certain conditions. As of December 31, 2024, there were no outstanding borrowings under the Revolving Credit Facility.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2012 Stock Plan Prior to the initial public offering ("IPO"), the Company maintained the 2012 Stock Plan (the “2012 Plan”), which provided for the grant of incentive stock options ("ISOs"), non-qualified stock options ("NSOs"), common stock of the Company, stock payments and restricted stock units. The 2012 Plan was initially adopted on December 6, 2012, and most recently amended and restated in March 2021. The 2012 Plan was terminated upon the effectiveness of the 2021 Incentive Award Plan in March 2021, and no further awards will be made under the 2012 Plan. 2021 Incentive Award Plan In March 2021, the Company’s board of directors adopted the 2021 Incentive Award Plan (the “2021 Plan”), which provides for the grant of NSOs, ISOs, stock appreciation rights (“SARs”), restricted stock, restricted stock units (including time-based restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”)), dividend equivalents and other stock or cash awards to employees, consultants and non-employee directors. Under the 2021 Plan, there are 49.2 million shares authorized to be issued, with 7.2 million shares still available for future issuance as of December 31, 2024. The shares available for future issuance as of December 31, 2024 may be issued as either Class A common stock or Class B common stock. 2022 Inducement Incentive Award Plan In April 2022, the Company’s board of directors adopted the 2022 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the grant of NSOs, SARs, restricted stock, RSUs, PSUs, dividend equivalents and other stock or cash awards to prospective employees. The Inducement Plan was amended on March 28, 2023 to add 13.3 million shares to the plan. Under the Inducement Plan, as of December 31, 2024, there are 18.3 million shares authorized to be issued, with 5.8 million shares still available for future issuance. The shares available for future issuance as of December 31, 2024 may be issued as Class A common stock. Stock-Based Compensation Expense Stock-based compensation expense is recognized on a straight-line basis over the requisite service period. Forfeitures are accounted for as they occur. The Company records stock-based compensation expense within Selling, general, and administrative expenses on the Consolidated Statements of Operations. The Company's stock-based compensation expense for the years ended December 31, 2024, 2023, and 2022 was $119.0 million, $166.8 million, and $112.3 million, respectively. The Company capitalized $9.1 million and $7.1 million of stock-based compensation expense related to internally developed software for the years ended December 31, 2024 and 2023, respectively. The Company did not capitalize any stock-based compensation expense for the year ended December 31, 2022. Stock Options Stock options granted under the 2012 Plan and 2021 Plan include ISOs and NSOs, generally have a maximum contractual term of 10 years, and typically vest over a four-year period. The following table summarizes the stock option award activity for the year ended December 31, 2024: Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Options Outstanding - December 31, 2023 26,378 $ 10.18 5.35 $ 15,700 Options granted 2 $ 18.48 Options exercised 7,810 $ 8.76 $ 71,687 Options canceled 626 $ 13.23 Options Outstanding - December 31, 2024 17,944 $ 10.69 4.87 $ 63,110 Options Exercisable at December 31, 2024 16,971 $ 10.87 4.68 $ 56,912 The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $10.65 and $3.74, respectively. There were no stock options granted during the year ended December 31, 2022. The aggregate intrinsic value of options exercised during the years ended December 31, 2024, 2023 and 2022 was $71.7 million, $8.5 million, and $1.0 million, respectively. Determination of Fair Value of Stock Options The fair value of stock options is estimated on the grant date using the Black-Scholes option-pricing model, which takes into account significant assumptions such as the expected term of the option, stock price volatility, and a risk-free rate of return. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period and contractual term. The table below summarizes the assumptions used during the years ended December 31, 2024 and 2023. There were no stock options granted during the year ended December 31, 2022. December 31, 2024 2023 Term in years 5 6.02 - 6.14 Risk free rate of return 3.8% 3.5% - 4.7% Expected volatility 65.0% 58.2% - 59.4% Dividend yield — % — % Compensation Expense – Stock Options For the years ended December 31, 2024, 2023 and 2022, the Company recorded compensation expense of $8.7 million, $12.0 million and $21.5 million respectively. As of December 31, 2024, the amount of unrecognized compensation expense for stock options is $3.4 million, which is expected to be recognized over a weighted-average period of 2.0 years. Restricted Stock Units RSUs represent the right to receive shares of the Company’s Class A or Class B common stock at a specified date in the future and typically have a vesting period of one The following table summarizes RSU award activity for the year ended December 31, 2024: RSUs Number of Shares Weighted Average Grant Date Fair Value Outstanding RSUs at December 31, 2023 21,723 $ 7.06 RSUs granted 5,076 $ 14.71 RSUs vested 11,437 $ 8.18 RSUs canceled 2,230 $ 8.27 Outstanding RSUs at December 31, 2024 13,132 $ 8.83 Determination of Fair Value of RSUs The fair value of RSUs granted is determined on the grant date based on the fair value of the Company's common stock. The total fair value of RSUs vested during the years ended December 31, 2024 and 2023 was $93.6 million and $89.7 million, respectively. Compensation Expense – RSUs For the years ended December 31, 2024, 2023 and 2022, the Company recorded compensation expense of $95.0 million, $90.0 million and $65.5 million, respectively. As of December 31, 2024, the amount of unrecognized compensation expense for RSUs is $101.2 million, which is expected to be recognized over a weighted-average period of 1.6 years. Performance-based Restricted Stock Units PSUs represent the right to receive shares of the Company’s Class A or Class B common stock at a specified date in the future based on pre-determined performance and service conditions. The PSUs granted include awards with a market condition, which are eligible to vest based on the achievement of predetermined stock price goals, and awards with performance conditions, which are eligible to vest based on the Company’s predetermined financial targets. For PSUs with predetermined financial targets, the number of shares that may vest ranges from 0% to 200% of the target amount. These PSUs cliff vest at the end of a three-year performance period. Additionally, the ultimate payout of the PSUs is subject to a relative total shareholder return (“TSR”) performance modifier, which adjusts the payout level upwards or downwards based on the Company’s shareholder return over the same three-year performance period relative to companies in a peer group established by the Company at the grant date. The following table summarizes PSU award activity for the year ended December 31, 2024: PSUs Number of Shares Weighted Average Grant Date Fair Value Outstanding PSUs at December 31, 2023 9,305 $ 4.37 PSUs granted 857 $ 24.03 PSUs vested 1,851 $ 8.68 PSUs canceled 99 $ 24.03 Outstanding PSUs at December 31, 2024 8,212 $ 5.21 Determination of Fair Value of PSUs The fair value of PSUs with performance conditions is determined on the grant date based on the fair value of the Company's common stock. The fair value of PSUs with market conditions and financial targets with relative TSR modifiers are estimated on the grant date using a Monte Carlo simulation model, which utilizes multiple variables that determine the probability of satisfying the market conditions or level of relative TSR modification as stipulated in the award. The table below summarizes the assumptions used during the years ended December 31, 2024 and 2023 . There were no PSUs with market conditions granted during the year ended December 31, 2022. December 31, 2024 December 31, 2023 Grant date stock price $ 18.09 $ 6.74 Term in years 3.0 3.0 Expected volatility 66.2 % 59.9 % Risk-free rate 4.6 % 3.6 % Dividend yield — % — % Cancellation of the Founders Awards – PSUs On March 28, 2023, the Company’s Co-Founders, Mario Schlosser (the Company’s President of Technology and Chief Technology Officer and former Chief Executive Officer) and Joshua Kushner (the Company’s Vice Chairman), recommended to the Company’s board of directors that they should cancel and terminate the applicable awards that were granted to them in connection with the Company’s IPO (the “Founders Awards”). Mr. Schlosser and Mr. Kushner each entered into an agreement to cancel and terminate his Founders Award, which consisted of performance-based restricted stock units covering 4,229,853 shares (for Mr. Schlosser) and 2,114,926 shares (for Mr. Kushner) of the Company’s Class A common stock. As a result of this cancellation, the Company recognized approximately $46.3 million of accelerated stock-based compensation expense that would have otherwise been recognized over the remaining vesting period of the awards. Compensation Expense – PSUs For the years ended December 31, 2024, 2023 and 2022 the Company recorded compensation expense of $15.3 million, $64.9 million, and $25.3 million respectively. As of December 31, 2024, the amount of unrecognized compensation expense for PSUs is $23.9 million, which is expected to be recognized over a weighted-average period of 1.7 years.

REINSURANCE

REINSURANCE	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
REINSURANCE	REINSURANCE The Company participates in quota share reinsurance to limit risk and capital requirements and XOL reinsurance to mitigate the exposure of high cost or catastrophic member risk. The quota share reinsurance arrangements are with more than one counterparty with multiple state-level treaties. The XOL reinsurance arrangements are with a private counterparty and federal and state-run programs. The Company also operates under an assumed reinsurance contract, under which the Company shares proportionally in all premiums and claims underwritten for the Cigna+Oscar Small Group offering. Reinsurance Contracts Accounted for under Deposit Accounting Reinsurance contracts that do not meet risk transfer requirements are accounted for under the deposit accounting method. Under deposit accounting, the contract is recorded as a financing, with no impact to premium revenues or medical expenses. The premiums earned and claims incurred that would have otherwise been ceded under reinsurance accounting are recorded on a net basis on the Consolidated Balance Sheets as a deposit liability within Accounts payable and other liabilities, respectively. As of December 31, 2024 and December 31, 2023, a deposit liability balance of $13.6 million and $7.0 million, respectively, was recorded for the Company's quota share arrangements accounted for under deposit accounting and represents fees due to the reinsurer, which are recognized within Selling, general, and administrative expenses on the Consolidated Statements of Operations. For the years ended December 31, 2024, 2023, and 2022, the Company ceded 53%, 45%, and 18% of its premium under reinsurance contracts accounted for under deposit accounting, respectively. Reinsurance Contracts Accounted for under Reinsurance Accounting When significant risk is transferred to the reinsurer, reinsurance accounting is required. Reinsurance accounting applies to quota share reinsurance contracts that are in runoff as well as the XOL treaties. Under reinsurance accounting, the Company records premium paid to the reinsurer as a reduction to premium revenue with a corresponding reinsurance payable. In the case of federal and state-run reinsurance programs, no reinsurance premiums are paid. Expected reimbursement from the reinsurer for claims incurred are recorded as a reduction to claims incurred with a corresponding reinsurance recoverable asset. The tables below present information for the Company's reinsurance arrangements accounted for under reinsurance accounting. See Note 4 - Revenue Recognition for total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total Premium revenue in the Consolidated Statements of Operations. The following table reconciles total Medical expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, (in thousands) 2024 2023 2022 Direct claims incurred $ 7,278,267 $ 4,459,702 $ 4,428,000 Ceded reinsurance claims (159,132) (44,736) (1,290,349) Assumed reinsurance claims 213,454 227,058 143,147 Medical expenses $ 7,332,589 $ 4,642,024 $ 3,280,798 The Company records Selling, general and administrative ("SG&A") expenses net of reinsurance ceding commissions and assumed SG&A expenses. The following table reconciles total Selling, general and administrative expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, 2024 (in thousands) 2024 2023 2022 Selling, general and administrative expenses, gross $ 1,755,942 $ 1,424,763 $ 1,419,370 Reinsurance ceding commissions (377) 1,003 (161,946) Selling, general and administrative expenses $ 1,755,565 $ 1,425,766 $ 1,257,424 The composition of the Reinsurance recoverable balance on the Consolidated Balance Sheets is as follows: December 31, (in thousands) 2024 2023 Reinsurance premium and claim recoverables $ 288,878 $ 224,837 Reinsurance ceding commissions 6,996 7,054 Experience refunds on reinsurance agreements (4,338) 9,303 Reinsurance recoverable $ 291,537 $ 241,194 Credit Ratings The financial condition of the Company's reinsurers is regularly evaluated to minimize exposure to significant losses. A key credit quality indicator for reinsurance is the financial strength ratings issued by the credit rating agencies, which provide an independent opinion of a reinsurer’s ability to meet ongoing obligations to policyholders. The Company’s reinsurers have most recently been issued financial strength ratings of A1 or higher. The creditworthiness of each reinsurer is evaluated in order to assess counterparty credit risk and estimate an allowance for expected credit losses on the Company's reinsurance recoverable balances.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The current income tax provision reflects the tax consequences of revenues and expenses currently taxable or deductible for the year reported. The deferred income tax provision or benefit reflects the differences between the financial and income tax reporting bases of the Company’s underlying assets and liabilities. The components of the provision for income taxes are as follows for the periods indicated: Years Ended December 31, (in thousands) 2024 2023 2022 Current income tax expense (benefit): Federal $ 2,219 $ 3,222 $ (358) State 7,424 14 — Total current income tax expense (benefit) $ 9,643 $ 3,236 $ (358) Deferred income (benefit) tax: Federal $ 73 $ 58 $ (165) State (2,411) — — Total deferred tax (benefit) $ (2,338) $ 58 $ (165) Total income tax expense (benefit) $ 7,305 $ 3,294 $ (523) A reconciliation of the tax provision at the U.S. federal statutory tax rate to the provision for income taxes and the effective tax rate follows for the periods indicated: Year Ended December 31, (in thousands, except percentages) 2024 2023 2022 Income (loss) before income taxes $ 33,426 $ (267,300) $ (610,075) Income tax benefit at statutory rate 21.00 % 21.00 % 21.00 % State taxes (net of federal income tax) 17.16 % (1.23) % 6.00 % Change in valuation allowance (10.88) % (11.08) % (23.27) % Stock-based compensation adjustment (99.52) % (1.65) % (1.92) % Non-deductible compensation 91.80 % (8.36) % (1.56) % Other permanent items 2.30 % 0.09 % (0.16) % Total income tax 21.86 % (1.23) % 0.09 % Deferred income tax assets and liabilities are recognized for the differences between the financial and income tax reporting bases of assets and liabilities based on enacted tax rates and laws. The components of deferred income tax assets and liabilities are as follows for the periods indicated: December 31, (in thousands) 2024 2023 Deferred Tax Assets: Net operating loss ("NOL") carryforwards $ 525,056 $ 548,147 Claims reserves 27,282 17,736 Deposit accounting 15,330 — Fixed assets and capitalized software 7,968 6,600 Accrued bonus 7,652 5,786 Allowance for credit loss 6,573 6,636 Unearned premium reserve 3,370 2,756 Stock option 2,824 2,396 Start-up costs 2,364 2,805 Unrealized losses 383 21 Premium deficiency reserves — 1,213 Other 5,932 6,568 Total deferred tax assets before valuation allowance 604,734 600,664 Valuation allowance 590,629 591,701 Total deferred tax assets, net of valuation allowance $ 14,105 $ 8,963 Deferred Tax Liabilities: Investments 5,131 2,553 Prepaid expenses 3,204 2,830 Unrealized gains 54 295 Other 2,676 2,581 Total deferred tax liabilities 11,065 8,259 Net deferred tax assets $ 3,040 $ 704 The Company evaluates the need for a valuation allowance against its deferred tax assets considering all available positive and negative evidence. Based on its analysis, the Company concluded that it is more likely than not that all or some portion of the deferred tax asset will not be realized. The Company has a valuation allowance of $590.6 million at December 31, 2024 against its deferred tax assets, including federal and state net operating losses, as the Company does not have a history of positive earnings. Valuation allowances will be provided until it becomes more likely than not that the benefit of the federal and state deferred tax assets will be realized. Federal NOL carryovers are $2,156.8 million, of which $1,249.0 million expire beginning in 2035 through 2043, and $907.8 million have indefinite carryforward periods. State NOL carryforwards from group filings are approximately $1,001.5 million and from separate entity filings are $298.9 million; state NOL carryforwards expire beginning in 2035. Pursuant to I.R.C Section 382, the Company underwent a change in ownership in 2016. Based on the annual limitation, use of pre-change NOL carryforwards will not be limited prior to expiration. The Company evaluates tax positions to determine whether the benefits are more likely than not to be sustained on audit based on technical merits. The Company did not have any uncertain tax positions for the years ended December 31, 2024, 2023, and 2022. The Company does not expect any significant changes to unrecognized tax benefits in the next twelve months. The Company’s policy is to classify interest accrued related to unrecognized tax benefits in interest expense while penalties are included in income tax expense. The Company had no interest or penalties related to uncertain tax positions. The Company currently files income tax returns in the United States, various states, and localities. The majority of the Company’s operating subsidiaries are included in a consolidated federal income tax return. The Company began operations in 2012 and has never been placed under income tax audit. Federal tax returns are open for examination for tax years from 2021. State tax returns are open for examination for tax years from 2020.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
LEASES	LEASES The Company records right-of-use ("ROU") assets and lease liabilities for its real estate operating leases. Leases with an initial term of twelve months or less are not recorded on the balance sheet. The following table presents the lease-related balances within the balance sheet: December 31, (in thousands) Balance Sheet Classification 2024 2023 Operating Leases Right-of-use assets Other assets $ 57,153 $ 62,873 Lease liabilities, current Accounts payable and accrued liabilities $ 13,548 $ 14,175 Lease liabilities, noncurrent Other liabilities $ 60,651 $ 66,803 Operating lease expense was $14.5 million, $14.7 million, and $14.8 million for the years ended December 31, 2024, 2023, and 2022, respectively, which includes variable lease expense. Cash paid for amounts included in the measurement of lease liabilities was $14.2 million and $14.0 million for the years ended December 31, 2024 and 2023, respectively. Future minimum rental payments under non-cancellable operating leases are estimated as follows: Year Ended December 31, (in thousands) 2025 $ 13,548 2026 16,445 2027 17,099 2028 17,168 2029 17,238 Thereafter 20,881 Total lease payments $ 102,379 Less: Imputed interest 28,180 Present value of lease liabilities $ 74,199 Additional Information: December 31, 2024 Weighted-average remaining lease term 6.2 years Weighted-average discount rate 10.65 %

PROPERTY, EQUIPMENT AND CAPITAL

PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE	PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE The following table summarizes the balances of the Company’s property, equipment, and capitalized software: December 31, (in thousands) 2024 2023 Property, equipment, and capitalized software Software and hardware $ 148,260 $ 119,263 Leasehold improvements 26,386 25,301 Property and fixtures 6,248 5,443 Property, equipment, and capitalized software 180,894 150,007 Less: Accumulated depreciation and amortization (114,101) (88,077) Property, equipment, and capitalized software, net $ 66,793 $ 61,930

BUSINESS ARRANGEMENTS

BUSINESS ARRANGEMENTS	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ARRANGEMENTS	BUSINESS ARRANGEMENTS Variable Interest Entities In the normal course of business, the Company enters into business arrangements with integrated health systems and several medical professional corporations that employ healthcare providers to deliver telemedical healthcare services to its covered member population in various states. The financial results of these entities are consolidated into the Company's financial statements. The following table presents the collective assets and liabilities of the Company's variable interest entities: As of December 31, (in thousands) 2024 2023 Assets $ 102,550 $ 90,683 Liabilities $ 63,114 $ 58,332

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS' EQUITY Common Stock The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting, conversion, and transfer rights. Voting Rights Holders of the Company’s Class A common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, and holders of the Company’s Class B common stock are entitled to 20 votes for each share held on all matters submitted to a vote of stockholders. The holders of the Company’s Class A common stock and Class B common stock will vote together as a single class, unless otherwise required by law or under the Amended and Restated Certificate of Incorporation. Conversion and Transfer Each outstanding share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. Each share of Class B common stock will convert automatically into one share of Class A Common Stock upon any transfer, except for certain permitted transfers described in the Amended and Restated Certificate of Incorporation. All outstanding shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis upon the date that is the earlier of (i) the transfer of Class B common stock to a person or entity that is not in the transferor’s permitted ownership group, as described in the Amended and Restated Certificate of Incorporation, (ii) March 2, 2028, or (iii) upon the occurrence of certain other events as described in the Amended and Restated Certificate of Incorporation. Dividends Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any.

STATUTORY REGULATIONS

STATUTORY REGULATIONS	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION Premiums earned The composition of Premium revenue on the Consolidated Statement of Operations is as follows: Year Ended December 31, (in thousands) 2024 2023 2022 Direct policy premiums $ 10,292,125 $ 6,418,872 $ 6,704,330 Assumed premiums 219,572 228,786 138,109 Risk adjustment transfers (1,526,448) (950,680) (1,507,919) Reinsurance premiums ceded (13,990) (10,909) (1,463,403) Premium $ 8,971,259 $ 5,686,069 $ 3,871,117 The direct policy premiums earned from CMS as part of APTC and Medicare Advantage for the years ended December 31, 2024, 2023, and 2022 were $9,512.3 million, $5,521.9 million, and $5,730.1 million, respectively. The Company's insurance subsidiaries prepare financial statements in accordance with Statutory Accounting Principles ("SAP") prescribed or permitted by the insurance departments of their states of domicile. SAP are focused on the solvency of insurance companies and are designed to ensure that insurers maintain sufficient capital and surplus to meet their insurance-related obligations. The Company's insurance subsidiaries are regulated by the state insurance departments of the states in which they are domiciled. Statutory regulations include the establishment of minimum levels of statutory capital to be maintained by insurance subsidiaries and restrictions on dividend payments and other distributions made by the insurance subsidiaries to the parent company. Minimum statutory capital requirements differ by state and are based on minimum risk-based capital ("RBC") requirements developed by the National Association of Insurance Commissioners ("NAIC"). As of December 31, 2024, the Company's insurance subsidiaries are estimated to have an aggregate statutory capital and surplus of approximately $1,242.7 million. As of December 31, 2023, the Company’s insurance subsidiaries had an aggregate statutory capital and surplus of $800.6 million. Individually, each of the Company's insurance subsidiaries is projected to exceed the minimum required statutory capital and surplus and RBC minimum requirements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In February 2022, the Company issued the 2031 Notes to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital Management, LLC, LionTree Investment Management, LLC and Tenere Capital LLC (collectively, the “Purchasers”). See Note 9 - Debt for additional information. In addition, pursuant to the Investment Agreement entered into with the Purchasers, the Company agreed to amend the Twelfth Amended and Restated Investors' Rights Agreement dated as of March 5, 2021 (the “Investors’ Rights Agreement”), by and among the Company and the investors party thereto, to provide that the Notes and shares of Class A common stock issued or issuable upon conversion of any 2031 Notes held by entities affiliated with Thrive Capital will be subject to the registration rights contained in the Investors' Rights Agreement.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company’s current and past business practices are subject to review or other investigations by various state insurance and healthcare regulatory authorities and other state and federal regulatory authorities. These reviews focus on numerous facets of the Company’s business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, network adequacy, utilization management practices, pharmacy benefits, access to care, and sales practices, among others. Some of these reviews have historically resulted in fines imposed on the Company and some have required changes to certain of the Company’s practices. The Company continues to be subject to these reviews, which could result in additional fines or other sanctions being imposed on the Company or additional changes to certain of its practices. The Company is also currently involved in, and may in the future from time to time become involved in, legal proceedings and other claims in the ordinary course of its business, including class actions and suits brought by the Company’s members, providers, commercial counterparties, employees, and other parties relating to the Company’s business, including management and administration of health benefit plans and other services. Such matters can include claims relating to the performance of contractual and non-contractual obligations to providers, members, employer groups, and others, including, but not limited to, the alleged failure to properly pay in-network and out-of-network claims and challenges to the manner in which the Company processes claims, various employment claims, disputes regarding reinsurance arrangements, disputes relating to intellectual property, privacy, the Telephone Consumer Protection Act and class action lawsuits, or other, and claims alleging that the Company has engaged in unfair business practices. In addition, on May 12, 2022, a securities class action lawsuit against the Company, certain of its directors and officers, and the underwriters that participated in the Company’s IPO was commenced in the United States District Court for the Southern District of New York, captioned Carpenter v. Oscar Health, Inc., et al., Case No. 1:22-CV-03885 (S.D.N.Y.) (the “Securities Action”). The initial complaint in the Securities Action asserted violations of Sections 11 and 15 of the Securities Act based on the Company’s purported failure to disclose in its IPO registration statement growing COVID-19 testing and treatment costs, the impact of significant Special Enrollment Period membership, and risk adjustment data validation results for 2019 and 2020. By Court orders dated September 27, 2022 and December 13, 2022, the Court appointed a lead plaintiff and lead counsel on behalf of the putative class. An amended complaint filed on December 6, 2022 asserts the same violations of Sections 11 and 15 of the Securities Act, but this time based on the Company’s alleged failure to disclose in its IPO registration statement purportedly inadequate controls and systems in connection with the risk adjustment data validation audit for 2019, alleging that this purported omission caused losses and damages for members of the putative class. The amended complaint seeks unspecified compensatory damages as well as interest, fees, and costs. On April 4, 2023, the Company moved to dismiss the amended complaint. Briefing on the motion was completed on July 7, 2023. The Company believes it has meritorious defenses to these claims. At this time, the Company cannot predict the outcome, or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter. The Company records liabilities for its reasonable estimates of probable losses resulting from these matters where appropriate. Estimates of losses resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred, the ultimate settlement of which could be material. Given that such proceedings are subject to uncertainty, there can be no assurance that such legal proceedings, either individually or in the aggregate, will not have a material adverse effect on Oscar's business, results of operations, financial condition or cash flows.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company operates in and reports as a single reportable segment as the CODM does not evaluate profitability nor evaluate performance or allocate resources below the level of the consolidated Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM reviews Net income (loss) attributable to Oscar Health, Inc. and Adjusted EBITDA presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented. As part of the adoption of ASU 2023-07, the prior years’ segment information has been disclosed herein to align with the current year’s presentation. The following table presents the revenue, significant expenses, and net income (loss) for the Company’s segment. As the Company operates and reports as a single segment, its measure of segment net income (loss) is the same as Net income (loss) attributable to Oscar Health, Inc. on the Consolidated Statements of Operations. Year Ended December 31, (in thousands) 2024 2023 2022 Total Revenue $ 9,177,564 $ 5,862,869 $ 3,963,638 Less: Medical expenses 7,332,589 4,642,024 3,280,798 Selling, general, and administrative expenses: Member acquisition and servicing costs (1) 747,627 540,135 679,464 Premium taxes, exchange fees, and other taxes and fees (2) 432,290 289,388 281,518 All other SG&A (3) 575,648 596,243 296,442 Total Selling, general, and administrative expenses 1,755,565 1,425,766 1,257,424 Depreciation and amortization 32,145 30,694 15,283 Earnings (loss) from operations 57,265 (235,615) (589,867) Interest expense 23,734 24,603 22,623 Other expense (income) 105 7,082 (2,415) Earnings (loss) before income taxes 33,426 (267,300) (610,075) Income tax expense (benefit) 7,305 3,294 (523) Net income (loss) attributable to noncontrolling interests 689 134 (3,277) Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) (1) Member acquisition and servicing costs include the Company’s expenses incurred to acquire, service, and fulfill obligations to members. (2) Premium taxes, exchange fees, and other taxes and fees represent non-income tax charges from federal and state governments, including but not limited to healthcare exchange user fees and premium taxes. (3) All other SG&A includes employee-related and administrative costs that are not member-based. Additionally, all other SG&A includes the net impact of quota share reinsurance accounted for under deposit accounting. Significant Customers The Company generates the majority of its total revenue from health insurance policy premiums, which primarily comes from subsidies received from CMS as part of the APTC program.

SCHEDULE I - CONDENSED FINANCIA

SCHEDULE I - CONDENSED FINANCIAL INFORMATION	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED FINANCIAL INFORMATION	Oscar Health, Inc. Schedule I - Condensed Balance Sheets (Parent-Only) (in thousands, except per share amounts) December 31, 2024 December 31, 2023 Assets: Cash and cash equivalents $ 97,384 $ 171,940 Restricted deposits and investments 9,086 23,589 Investments in and advances to subsidiaries 1,207,848 925,926 Other assets 11,801 5,990 Total Assets $ 1,326,119 $ 1,127,445 Liabilities and Stockholders' Equity Long-term debt $ 299,555 $ 298,777 Other liabilities 12,978 24,701 Total liabilities 312,533 323,478 Commitments and contingencies Stockholders' Equity Class A common stock $0.00001 par value; 825,000 thousand shares authorized, 214,974 thousand and 193,875 thousand shares outstanding as of December 31, 2024 and 2023, respectively 2 2 Class B common stock, $0.00001 par value; 82,500 thousand shares authorized, 35,514 thousand shares outstanding as of December 31, 2024 and 2023, respectively — — Treasury stock (315 thousand shares as of December 31, 2024 and 2023) (2,923) (2,923) Additional paid-in capital 3,869,617 3,682,294 Accumulated deficit (2,851,283) (2,876,715) Accumulated other comprehensive income (loss) (1,827) 1,309 Total Oscar Health, Inc. Stockholders’ Equity 1,013,586 803,967 Total Liabilities and Stockholders' Equity $ 1,326,119 $ 1,127,445 Oscar Health, Inc. Schedule I - Condensed Statements of Operations (Parent-Only) Year Ended December 31, (in thousands) 2024 2023 2022 Revenue Investment income and other revenue $ 16,714 $ 20,253 $ 8,274 Total revenue 16,714 20,253 8,274 Operating Expenses General and administrative expenses 118,566 106,387 60,130 Interest expense 23,697 24,577 22,583 Other expenses (income) 110 7,081 (2,415) Loss before income tax (benefit) expense and equity in net loss of subsidiaries (125,659) (117,792) (72,024) Income tax (benefit) provision (34,777) (7,870) 2,703 Loss before equity in net loss of subsidiaries (90,882) (109,922) (74,727) Equity in net income (loss) of subsidiaries 116,314 (160,806) (531,548) Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) Oscar Health, Inc. Schedule I - Condensed Statements of Comprehensive Income (Parent-Only) Year Ended December 31, (in thousands) 2024 2023 2022 Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) Other comprehensive income (loss), net of tax: Net unrealized gains (losses) on securities available for sale (3,136) 11,024 (6,044) Comprehensive income (loss) attributable to Oscar Health, Inc. $ 22,296 $ (259,704) $ (612,319) Oscar Health, Inc. Schedule I - Condensed Statements of Cash Flows (Parent-Only) Year Ended December 31, (in thousands) 2024 2023 2022 Net cash (used in) provided by operating activities $ 2,103 $ 9,055 $ (3,957) Cash flows from investing activities: Investments in subsidiaries (159,628) (149,025) (652,008) Purchase of investments (2,409) — — Purchase of fixed maturity securities — — (138,919) Sale of investments — (15,775) 295,316 Maturity of investments 16,990 306,511 155,578 Net cash (used in) provided by investing activities (145,047) 141,711 (340,033) Cash flows from financing activities: Proceeds from long-term debt — — 305,000 Proceeds from joint venture contribution — 2,490 1,846 Proceeds from exercise of stock options 68,388 3,956 1,299 Payment of debt issuance costs — — (7,035) Net cash provided by financing activities 68,388 6,446 301,110 Increase (decrease) in cash, cash equivalents and restricted cash equivalents (74,556) 157,212 (42,880) Cash, cash equivalents, restricted cash and cash equivalents—beginning of period 171,940 14,728 57,608 Cash, cash equivalents , restricted cash and cash equivalents—end of period $ 97,384 $ 171,940 $ 14,728

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 25,432	$ (270,728)	$ (606,275)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 6, 2024, Ranmali Bopitiya, the Company's Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 98,411 shares of the Company’s Class A common stock by September 7, 2025.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Ranmali Bopitiya [Member]
Trading Arrangements, by Individual
Name	Ranmali Bopitiya
Title	Company's Chief Legal Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 6, 2024
Expiration Date	September 7, 2025
Arrangement Duration	275 days
Aggregate Available	98,411	98,411

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity Risk Management and Strategy We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information, including protected health information and the systems that store and transmit such data. Our cybersecurity risk management program includes a cybersecurity incident response plan. We use the ISO 27001 standard as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. This does not imply that we meet any particular technical standards, specifications or requirements. Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas. Our cybersecurity risk management program includes: • risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment; • a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents; • the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls, and conduct tabletop exercises to validate our cybersecurity incident response processes; • the use of various technology and process-based methods, such as network isolation, intrusion detection systems, vulnerability assessments, penetration testing, use of threat intelligence, content filtering, endpoint security (including anti-malware and detection response capabilities), email security mechanisms, and access control mechanisms; • cybersecurity awareness training of our employees, including incident response personnel and senior management; • a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and • a third-party risk management and diligence process for vendors and service providers. While we have implemented processes to maintain our cybersecurity risk management program, there can be no assurance that our program, including our controls, procedures and processes, will be fully complied with or that it will be fully effective in protecting the confidentiality, integrity and availability of our critical systems and information.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to t he Audit
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to t he Audit
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Management provides quarterly
Cybersecurity Risk Role of Management [Text Block]	Management provides quarterly reports on our cybersecurity risks to the Committee. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents. The Committee reports to the full Board regarding its activities, including those related to cybersecurity. Our management team, including our Chief Technology Officer and Chief Information Security Officer (CISO), is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our Chief Technology Officer, the Company’s co-founder and former CEO, has extensive experience in computer science and technology, including as a visiting scholar at Stanford University. This experience has enhanced his expertise in cybersecurity governance and risk management. Our CISO is a Certified Information Systems Security Professional and his experience includes over 20 years of working in the cybersecurity field in various industries, including data analytics, identity verification software, and financial services industries, and 15 years leading teams and programs . Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from the Health Information Sharing and Analysis Center and other governmental, public or private sources; and alerts and reports produced by security tools deployed in the IT environment.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our management team, including our Chief Technology Officer and Chief Information Security Officer (CISO), is responsible for assessing and managing our material risks from cybersecurity threats.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our Chief Technology Officer, the Company’s co-founder and former CEO, has extensive experience in computer science and technology, including as a visiting scholar at Stanford University. This experience has enhanced his expertise in cybersecurity governance and risk management. Our CISO is a Certified Information Systems Security Professional and his experience includes over 20 years of working in the cybersecurity field in various industries, including data analytics, identity verification software, and financial services industries, and 15 years leading teams and programs
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Management provides quarterly
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	The Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Consolidated Financial Statements include the accounts of the Company, all of the controlled subsidiaries and variable interest entities of which the Company is the primary beneficiary. Noncontrolling interest consists of equity that is not attributable directly or indirectly to the Company. All material intercompany transactions have been eliminated in consolidation. Balances (except per share data) are presented in U.S. dollars and rounded, as indicated. In order to preserve the mathematical accuracy of the underlying calculations, immaterial footing differences may occur between the sum of individual balances and the total balances presented.
Reclassification	With the commencement of the current fiscal year, the Company has made certain reclassifications to the income statement to provide more transparency into the Company’s streams of revenue and to increase comparability with peers. This reclassification has been applied retrospectively, and comparative figures for prior periods have been adjusted accordingly within the accompanying Consolidated Financial Statements. The reclassification does not affect the Company’s Net income.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements. Significant estimates inherent in the preparation of the accompanying audited Consolidated Financial Statements include healthcare costs incurred but not yet reported (“IBNR”) and risk adjustment transfers. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ materially from these estimates.
Segment Information	Oscar operates as one reportable segment to sell insurance to its members through the federal and state-run healthcare exchanges formed in conjunction with the ACA and leverages its technology platform to provide services via its +Oscar Offering. The Company determined that our Chief Executive Officer is the chief operating decision maker (“CODM”) who regularly reviews financial information and other key performance indicators on a consolidated basis, for the purposes of allocating resources and evaluating financial performance. Factors used in determining the reportable segment include the nature of operating activities, the Company’s organizational and reporting structure, and the type of information presented to the Company’s CODM to allocate resources and evaluate financial performance.
Revenue	Premium Premium revenue includes direct policy premiums collected directly from members and subsidies received from the Centers for Medicare & Medicaid Services (“CMS”) as part of the Advanced Premium Tax Credit (“APTC”) and Medicare Advantage programs, along with assumed premiums from the Company's reinsurance agreement. Premium revenue is adjusted for the estimated impact of the risk adjustment program required by CMS. Total premiums earned is net of ceded premium from excess of loss (“XOL”) and run-off quota share reinsurance contracts accounted for under reinsurance accounting. The Company receives a fixed premium per member per month and recognizes premium revenue during the period in which it is obligated to provide services to its members. For direct policy premiums received from CMS, revenue is recorded based on membership and eligibility criteria provided by CMS and is subject to monthly adjustment by CMS. The Company earns revenue as part of services performed via the +Oscar platform. Services revenue is recognized in the period the contractual performance obligations are satisfied and measured in an amount that reflects the consideration the Company expects to be entitled to in exchange for performing the services. The timing of the Company's revenue recognition may differ from the timing of payment by customers. A receivable is recorded to Premiums and accounts receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, deferred revenue is recorded to Accounts payable and other liabilities when payment is received before the performance obligations are satisfied. Other revenue includes primarily sublease income.
Affordable Care Act (“ACA”)	The Company conducts business through the federal and state-run healthcare exchanges formed in conjunction with ACA and is therefore subject to certain risk stabilization programs and fees established by ACA, such as: Risk Adjustment and Minimum Medical Loss Ratio (“MLR”) requirements. The ACA risk adjustment program is administered federally by CMS. Under this program, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores relative to the estimated market average risk score, when applied to the statewide average premium, will have a risk adjustment payable into the pool. Inversely, plans with higher than average risk scores relative to the estimated market average risk score, when applied to the statewide average premium, will have a risk adjustment receivable from the pool. Management develops its membership risk scores for the risk adjustment payable using actuarial methodologies and assumptions and by analyzing member data, including demographic and projections of claims data expected to be submitted by the Company to CMS for settlement. Generally, the estimated market average risk score and statewide average premium are obtained from third party surveys of other insurance plans. There is judgment in estimating the Company’s membership risk scores and the estimated market average risk scores. Management refines its estimate as new information becomes available and the final report on actual market risk scores is received from CMS in June of the following year. In addition, CMS and the Office of Inspector General for Health and Human Services (“HHS”) perform risk adjustment data validation (“RADV”) audits of health insurance plans to validate the coding practices of and supporting documentation maintained by healthcare providers, and such audits have in the past and may in the future result in adjustments to risk transfer payments. The ACA established a minimum MLR ratio that requires insurers to pay rebates to customers when MLR is below established thresholds. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue for purposes of calculating the required minimum MLR. The Company records estimated MLR rebates as an adjustment to premium revenue.
Reinsurance	The Company participates in reinsurance agreements to limit risk and meet its capital requirements. The Company currently enters into two different types of arrangements: quota share reinsurance contracts that do not meet risk transfer requirements and XOL reinsurance contracts. The quota share reinsurance contracts are accounted for under the deposit accounting method. Under deposit accounting, the contract is recorded as a financing, with no impact to premium revenue or medical expenses. In XOL reinsurance, the reinsurer agrees to assume all or a portion of the ceding company’s losses in excess of a specified amount. Under XOL reinsurance, the premium payable to the reinsurer is negotiated by the parties based on losses on an individual member in a given calendar year and their assessment of the amount of risk being ceded to the reinsurer. Premiums under XOL reinsurance agreements are based on enrollment calculated on a per member per month basis. The XOL contracts are accounted for under reinsurance accounting and, as such, the Company records premium paid to the reinsurer as a reduction to premium revenue. In the case of federal and state-run reinsurance programs, no reinsurance premiums are paid. Expected reimbursement from the reinsurer for claims incurred are recorded as a reduction to medical expenses. Reinsurance contracts are renewed periodically and we review them in advance of the contract’s expiration to negotiate terms for new reinsurance contracts. During each renewal cycle, there are a number of factors considered when determining reinsurance coverage, including (1) plans to change the underlying insurance coverage offered by the Company, (2) trends in loss activity, (3) the level of the insurance subsidiaries' capital and surplus, (4) changes in the Company's risk appetite, and (5) the cost and availability of reinsurance coverage.
Premium Deficiency Reserve	Premium deficiency reserve (“PDR”) liabilities are established when it is probable that expected future claims and maintenance expenses will exceed future premium and reinsurance recoveries based on existing insurance contract terms including consideration of net investment income. For purposes of determining premium deficiency reserves, contracts are grouped consistent with the Company’s method of acquiring, servicing, and measuring the profitability of such contracts, which is generally on a line of business basis.
Cash and Cash Equivalents	Cash and cash equivalents consists of highly liquid investments with original maturities of three months or less.
Restricted Deposits	The Company defines restricted deposits as restricted cash, cash equivalents, and investments maintained on deposit or pledged primarily to various state agencies in connection with its insurance licensure. Statutory regulations require these amounts to remain on deposit indefinitely; therefore, the Company classifies these restricted deposits as long-term regardless of the contractual maturity date of the securities held. Restricted cash equivalents and investments are recorded at fair value.
Investments	The majority of the Company's investments are classified as available-for-sale and are carried at fair value. Short-term investments include securities with maturities between three months and one year. Long-term investments include securities with maturities greater than one year.
Allowance for Credit Losses	Premium and other receivables primarily includes insurance premiums due from CMS and members, pharmaceutical rebates, and other claims-related provider receivables and are reported net of any allowance for credit losses. Receivable balances are also recorded related to the Company's risk adjustment program, reinsurance program, and value-based care arrangements. An allowance for credit losses is generally calculated based on historical collection experience, the counterparty's creditworthiness, and consideration of current and future economic events.
Policy Acquisition Cost	Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include broker commissions, costs of policy issuance and underwriting, and other costs incurred to acquire new business or renew existing business. Policy acquisition costs, other than broker bonus commissions, are expensed in the period incurred. Broker bonuses are capitalized and amortized over the policy term. The Company's short-duration policies typically have a one-year term and may be canceled by the member upon 30 days' notice.
Income Taxes	Income taxes are accounted for under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the bases of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be realized.
Benefits Payable	Benefits payable consists of liabilities for both IBNR and reported but not yet processed through the Company's systems that are determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. IBNR is an actuarial estimate, determined by employing actuarial methods, that is based on claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors. For low severity incurred but not paid claims, for the months prior to the most recent two months, the Company typically uses the completion factor development method. This methodology is a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project the Company's best estimate of claim liabilities. Under this method, historical paid claims data is formatted into claim triangles, which compare claim incurred dates to the dates of claim payments. This information is analyzed to create historical completion factors that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims. A seriatim methodology is utilized for high dollar claims which is supplemented by case management data supplied by medical and claims operations areas. For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they are primarily based on forecasted per member per month low dollar claims projections developed from the Company’s historical experience and adjusted for emerging experience data in the preceding months, which may include adjustments for known changes in estimates of recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality. Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes. These adjustments are made by the Company's actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing the Company's best estimate of reserves include changes in utilization levels, unit costs, member cost sharing, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, and claim submission patterns. The Company regularly reviews and sets assumptions regarding cost trends and utilization when initially establishing claim liabilities. The Company continually monitors and adjusts the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that the Company's assumptions regarding cost trends and utilization are materially different from actual results, the Company's income statement and financial position could be impacted in future periods. Adjustments of prior year estimates may result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of healthcare costs, adjustments to claim liabilities occur each period and are sometimes significant as compared to the net income recorded in that period. Prior period development is recognized immediately upon the actuary’s judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable. Disputed Claim Reserves The Company also records, as part of benefits payable, an estimate of the ultimate liability for actual and potential claims disputes by providers based on an analysis of historical per member per month (“PMPM”) dispute experience supplemented with current information on reported disputes. Since these liabilities are part of the overall claim reserve, they are proportionally ceded under the Company's reinsurance agreements for historical policy years with contracts in force. The disputed claim reserves included as part of the benefits payable balance was approximately $183.7 million and $241.1 million as of December 31, 2024 and 2023, respectively. Unallocated Claims Adjustment Expenses Claims adjustment expenses (“CAE”) are costs incurred or expected to be incurred in connection with the adjustment and recording of health claims not subject to reinsurance. Such expenses include, but are not limited to, case management, utilization review, and quality assurance and are intended to reduce the number of health services provided or the cost of such services. CAE is included in other insurance costs and the related CAE payable is included in accounts payable and accrued liabilities.
Property, Equipment and Capitalized Software	Property, equipment, and capitalized software are reported at cost less accumulated depreciation. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the related assets, which range from two three
Leases	The Company leases office space under operating leases expiring on various dates through 2032. On the lease commencement date, a right-of-use (“ROU”) asset and lease liability are recognized as Other assets and Other Liabilities on the Consolidated Balance Sheets based on the present value of the future minimum lease payments over the lease term. Since the Company's lease agreements do not provide an implicit rate, an incremental borrowing rate, based on the information available at commencement date, is used to determine the present value of future payments. The calculation of the ROU asset is based on the lease liability, and includes any lease payments made, and excludes lease incentives and initial direct costs incurred. The Company determines if an arrangement is a lease or contains a lease at inception of the arrangement based on the terms and conditions in the contract. Options to extend or terminate a lease at the Company's discretion are factored into the calculation of the lease liabilities and ROU assets only if the Company is reasonably certain it will exercise those options. Short-term leases with an initial term of twelve months or less are not recorded on the balance sheet.
Earnings Per Share	Earnings (loss) per share (“EPS”) is calculated using the two-class method, which is an earnings allocation model that treats participating securities as having rights to earnings that otherwise would have been available to common stockholders. Under the two-class method, earnings for the period are required to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. For EPS computation purposes, the Company's Class A and Class B common stock are considered one single class of common stock because both classes have the same dividend and liquidation rights. Refer to Note 3 - Earnings (Loss) Per Share for a description of our basic and diluted EPS calculations.
Variable Interest Entities	The Company enters arrangements with various entities that are deemed to be variable interest entities (“VIE”). A VIE is an entity that either (1) has equity investors that lack certain essential characteristics of a controlling financial interest (including the ability to control activities of the entity, the obligation to absorb the entity’s expected losses, and the right to receive the entity’s expected residual returns) or (2) lacks sufficient equity to finance its own activities without financial support provided by other entities, which in turn would be expected to absorb at least some of the expected losses of the VIE. The Company is deemed a primary beneficiary of a VIE if it has (1) the power to direct the activities of the VIE that most significantly impact the economic performance of the VIE and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could be potentially significant to the VIE. If both conditions are present, the Company is required to consolidate the VIE into its financial results.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Not Yet Adopted	In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which requires, for each reportable segment, disclosure of significant segment expense categories, other segment items, enhanced interim disclosures of certain segment-related disclosures that previously were only required annually, and other disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 and provided additional segment footnote disclosures in the Company's annual Consolidated Financial Statements for the year ending December 31, 2024. In addition, the Company provided enhanced disclosures regarding the measure of profit or loss reviewed by the CODM as well as enhanced expense disclosures. In December 2023, the FASB issued Accounting Standards Update No. 2023-09 ("ASU 2023-09"), Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which is intended to improve the transparency of income tax disclosures by requiring greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid and other amendments to improve the effectiveness of income tax disclosures. This guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. ASU 2023-09 applies on a prospective basis; however, retrospective application in all prior periods presented is permitted. While the standard will require additional disclosures related to the Company’s income taxes, the standard is not expected to have any material impact on the Company’s consolidated operating results, financial condition, or cash flows. The Company is currently evaluating the impact of the adoption of this guidance on the related disclosures before it becomes effective for the Company’s 2025 annual financial statements. In November 2024, the FASB issued Accounting Standards Update No. 2024-03 ("ASU 2024-03"), Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosures in the notes to financial statements, disaggregating specific expense categories for relevant income statement captions and additional disclosures of the Company's total amount of selling expenses. This guidance is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Consolidated Financial Statements.
Fair Value	The Company's financial assets and liabilities measured at fair value on a recurring basis are categorized into a three-level fair value hierarchy based on the priority of the inputs used in the fair value valuation technique. The levels of the fair value hierarchy are as follows: • Level 1 : Inputs utilize quoted (unadjusted) prices in active markets for identical assets or liabilities. • Level 2 : Inputs utilize quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations in which all significant inputs are observable in active markets. • Level 3 : Inputs utilized are unobservable but significant to the fair value measurement for the asset or liability. The unobservable inputs are used to measure fair value to the extent relevant observable inputs are not available. The unobservable inputs typically reflect management’s own estimates about the assumptions a market participant would use in pricing the asset or liability.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Premiums And Other Receivables, Allowance For Credit Loss	The Company has presented the rollforward related to its allowance for credit losses on our risk sharing receivables below: For the year ended December 31, (in thousands) 2024 2023 Beginning balance $ 31,600 $ 2,988 Provision for credit losses (300) 28,612 Ending balance $ 31,300 $ 31,600

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Schedule of premiums earned	Year Ended December 31, (in thousands) 2024 2023 2022 Direct policy premiums $ 10,292,125 $ 6,418,872 $ 6,704,330 Assumed premiums 219,572 228,786 138,109 Risk adjustment transfers (1,526,448) (950,680) (1,507,919) Reinsurance premiums ceded (13,990) (10,909) (1,463,403) Premium $ 8,971,259 $ 5,686,069 $ 3,871,117 The following table reconciles total Medical expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, (in thousands) 2024 2023 2022 Direct claims incurred $ 7,278,267 $ 4,459,702 $ 4,428,000 Ceded reinsurance claims (159,132) (44,736) (1,290,349) Assumed reinsurance claims 213,454 227,058 143,147 Medical expenses $ 7,332,589 $ 4,642,024 $ 3,280,798 The Company records Selling, general and administrative ("SG&A") expenses net of reinsurance ceding commissions and assumed SG&A expenses. The following table reconciles total Selling, general and administrative expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, 2024 (in thousands) 2024 2023 2022 Selling, general and administrative expenses, gross $ 1,755,942 $ 1,424,763 $ 1,419,370 Reinsurance ceding commissions (377) 1,003 (161,946) Selling, general and administrative expenses $ 1,755,565 $ 1,425,766 $ 1,257,424 The composition of the Reinsurance recoverable balance on the Consolidated Balance Sheets is as follows: December 31, (in thousands) 2024 2023 Reinsurance premium and claim recoverables $ 288,878 $ 224,837 Reinsurance ceding commissions 6,996 7,054 Experience refunds on reinsurance agreements (4,338) 9,303 Reinsurance recoverable $ 291,537 $ 241,194

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share	Basic EPS is computed by dividing net income (loss) attributable to Oscar Health, Inc. for the period by the weighted-average shares of common stock outstanding during the period. In periods when the Company is in a net loss position, potentially dilutive securities are excluded from the computation of diluted EPS because their inclusion would have an anti-dilutive effect. Thus, basic EPS is the same as diluted EPS. During periods of net income, diluted EPS is computed by dividing Net income attributable to Oscar Health, Inc. by the sum of the basic weighted-average shares of common stock outstanding and any dilutive potential common stock outstanding during the period, using the treasury stock method and the if-converted method for convertible senior notes, as described in Note 9 - Debt. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock units and, performance-based restricted stock units. For the year ended December 31, 2024, the impact of convertible senior notes was anti-dilutive on dilutive EPS, and therefore excluded from the computation below. The computation for basic and diluted EPS is as follows: Year Ended December 31, (in thousands, except per share data) 2024 2023 2022 Numerator : Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) Effect of convertible senior notes — — — Net income (loss) available to Oscar Health, Inc. common shareholders $ 25,432 $ (270,728) $ (606,275) Denominator : Weighted average shares of common stock outstanding, basic and diluted 240,386 221,655 212,475 Common stock equivalents 25,467 — — Effect of convertible senior notes — — — Weighted average shares of common stock and potential dilutive common shares outstanding 265,853 221,655 212,475 Net Earnings (Loss) per Share Basic $ 0.11 $ (1.22) $ (2.85) Diluted $ 0.10 $ (1.22) $ (2.85)
Schedule of antidilutive securities excluded from computation	The following potential common shares were excluded from the computation of diluted EPS because including them would have had an anti-dilutive effect: Year Ended December 31, (in thousands) 2024 2023 2022 Stock options to purchase common stock $ 1,249 $ 26,378 $ 28,729 Restricted stock units 346 21,723 17,596 Performance-based restricted stock units — 9,305 8,465 Shares underlying convertible notes (Note 9) 36,652 36,652 36,652 Total $ 38,247 $ 94,058 $ 91,442

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of investment income	Net investment income was attributable to the following: Year Ended December 31, (in thousands) 2024 2023 2022 Fixed maturity securities $ 82,085 $ 59,965 $ 10,713 Cash equivalents 98,618 90,152 22,121 Other (1) 5,823 6,148 (4,202) Investment income 186,526 156,265 28,632 Investment expense (797) (818) (1,038) Net investment income $ 185,729 $ 155,447 $ 27,594
Summary of investments	The following tables provide summaries of the Company's investments by major security type as of December 31, 2024 and 2023: December 31, 2024 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. treasury and agency securities $ 1,946,759 $ 6,631 $ (9,028) $ 1,944,362 Corporate notes 463,261 1,346 (799) 463,808 Certificate of deposit 29,136 — — 29,136 Other (1) 2,409 — — 2,409 Total $ 2,441,565 $ 7,977 $ (9,827) $ 2,439,715 (1) Includes equity securities without a readily determinable market value. December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. treasury and agency securities $ 802,288 $ 1,689 $ (1,062) $ 802,915 Corporate notes 234,908 854 (198) 235,564 Certificate of deposit 16,663 — — 16,663 Total $ 1,053,859 $ 2,543 $ (1,260) $ 1,055,142
Summary of investments in a gross unrealized loss position	The following tables present the estimated fair value and gross unrealized losses of fixed maturity securities in a gross unrealized loss position, by the length of time in which the securities have continuously been in that position, as of December 31, 2024 and 2023: December 31, 2024 Less than 12 Months 12 Months or Longer (in thousands, except no. of securities) Number of Securities Fair Value Gross Number of Securities Fair Value Gross U.S. treasury and agency securities 191 $ 730,938 $ (9,003) 6 $ 47,748 $ (25) Corporate notes 110 146,349 (799) — — — Total 301 $ 877,287 $ (9,802) 6 $ 47,748 $ (25) December 31, 2023 Less than 12 Months 12 Months or Longer (in thousands, except no. of securities) Number of Securities Fair Value Gross Number of Securities Fair Value Gross U.S. treasury and agency securities 69 $ 480,312 $ (995) 4 $ 24,551 $ (67) Corporate notes 64 79,024 (166) 19 5,545 (32) Total 133 $ 559,336 $ (1,161) 23 $ 30,096 $ (99)
Investments Classified by Contractual Maturity Date	The amortized cost and fair value of the Company's fixed maturity as of December 31, 2024 and 2023 by contractual maturity are shown below. Actual maturities of these securities could differ from their contractual maturities because issuers may have the right to call or prepay obligations, with or without penalties. December 31, 2024 December 31, 2023 (in thousands) Amortized Cost Fair Value Amortized Cost Fair Value Due in one year or less $ 623,465 $ 624,461 $ 690,694 $ 689,833 Due after one year through five years 1,815,691 1,812,845 363,165 365,309 Total $ 2,439,156 $ 2,437,306 $ 1,053,859 $ 1,055,142

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured on recurring basis	The following tables summarize fair value measurements by level for assets and liabilities measured at fair value on a recurring basis: December 31, 2024 (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurement Assets Cash equivalents $ 95,331 $ — $ — $ 95,331 Investments U.S. treasury and agency securities $ — $ 1,944,362 $ — $ 1,944,362 Corporate notes — 463,808 — 463,808 Certificate of deposit — 29,136 — 29,136 Restricted investments Certificates of deposit — — — — U.S. treasury securities — 6,946 — 6,946 Total assets $ 95,331 $ 2,444,252 $ — $ 2,539,583 December 31, 2023 (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurement Assets Cash equivalents $ 434,330 $ — $ — $ 434,330 Investments U.S. treasury and agency securities $ — $ 802,915 $ — $ 802,915 Corporate notes — 235,564 — 235,564 Certificate of deposit — 16,663 — 16,663 Restricted investments Certificate of deposit — 2,478 — 2,478 U.S. treasury securities — 5,736 — 5,736 Total assets $ 434,330 $ 1,063,356 $ — $ 1,497,686

RESTRICTED CASH AND RESTRICTE_2

RESTRICTED CASH AND RESTRICTED DEPOSITS (Tables)	12 Months Ended
	Dec. 31, 2024
Cash and Cash Equivalents [Abstract]
Schedule of restricted deposits	The restricted cash and cash equivalents and restricted investments presented below are included in “restricted deposits” in the accompanying Consolidated Balance Sheets. As of December 31, (in thousands) 2024 2023 Restricted cash and cash equivalents $ 23,932 $ 21,656 Restricted investments 6,946 8,214 Restricted deposits $ 30,878 $ 29,870

BENEFITS PAYABLE (Tables)

BENEFITS PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table provides a rollforward of the Company’s beginning and ending Benefits payable and CAE payable balances for the years ended December 31, 2024, 2023, and 2022: Year Ended December 31, 2024 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 965,986 $ 13,192 $ 979,178 Less: Reinsurance recoverable 57,111 — 57,111 Benefits payable, beginning of the period, net $ 908,875 $ 13,192 $ 922,067 Claims incurred and CAE Current year $ 7,497,259 $ 108,492 $ 7,605,751 Prior years (164,670) — (164,670) Total claims incurred and CAE, net $ 7,332,589 $ 108,492 $ 7,441,081 Claims paid and CAE Current year $ 6,349,624 $ 92,758 $ 6,442,382 Prior years 593,745 10,685 604,430 Total claims and CAE paid, net $ 6,943,369 $ 103,443 $ 7,046,812 Benefits and CAE payable, end of period, net $ 1,298,095 $ 18,241 $ 1,316,336 Add: Reinsurance recoverable 58,635 — 58,635 Benefits and CAE payable, end of period $ 1,356,730 $ 18,241 $ 1,374,971 Year Ended December 31, 2023 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 937,727 $ 12,712 $ 950,439 Less: Reinsurance recoverable 277,944 — 277,944 Benefits payable, beginning of the period, net $ 659,783 $ 12,712 $ 672,495 Claims incurred and CAE Current year $ 4,622,263 $ 105,565 $ 4,727,828 Prior years 19,761 — 19,761 Total claims incurred and CAE, net $ 4,642,024 $ 105,565 $ 4,747,589 Claims paid and CAE Current year $ 3,840,009 $ 94,807 $ 3,934,816 Prior years 552,923 10,278 563,201 Total claims and CAE paid, net $ 4,392,932 $ 105,085 $ 4,498,017 Benefits and CAE payable, end of period, net $ 908,875 $ 13,192 $ 922,067 Add: Reinsurance recoverable 57,111 — 57,111 Benefits and CAE payable, end of period $ 965,986 $ 13,192 $ 979,178 Year Ended December 31, 2022 (in thousands) Benefits Payable Unallocated Claims Total Benefits payable, beginning of the period $ 513,582 $ 9,101 $ 522,683 Less: Reinsurance recoverable 159,180 — 159,180 Benefits payable, beginning of the period, net $ 354,402 $ 9,101 $ 363,503 Claims incurred and CAE Current year $ 3,279,460 $ 117,541 $ 3,397,001 Prior years 1,338 — 1,338 Total claims incurred and CAE, net $ 3,280,798 $ 117,541 $ 3,398,339 Claims paid and CAE Current year $ 2,726,912 $ 106,871 $ 2,833,783 Prior years 248,505 7,059 255,564 Total claims and CAE paid, net $ 2,975,417 $ 113,930 $ 3,089,347 Benefits and CAE payable, end of period, net $ 659,783 $ 12,712 $ 672,495 Add: Reinsurance recoverable 277,944 — 277,944 Benefits and CAE payable, end of period $ 937,727 $ 12,712 $ 950,439
Reconciliation of Claims Development to Liability	Incurred Healthcare Claims Net of Reinsurance Year Ended December 31, IBNR Cumulative number of reported claims (Unaudited) (Unaudited) (in thousands) 2022 2023 2024 Date of Service 2022 $ 3,279,461 $ 3,314,332 $ 3,310,967 $ 31,889 12,725 2023 4,622,263 4,469,672 95,688 11,526 2024 7,497,259 1,147,635 17,917 Total claims incurred $ 15,277,898 Cumulative Paid Healthcare Claims Net of Reinsurance Year Ended December 31, (Unaudited) (Unaudited) (in thousands) 2022 2023 2024 Date of Service 2022 $ 2,726,912 $ 3,223,917 $ 3,279,078 2023 3,840,009 4,373,984 2024 6,349,624 Total payment of incurred claims 14,002,686 All outstanding liabilities prior to 2022, net of reinsurance 22,883 Total benefits payable, net of reinsurance $ 1,298,095
Summary of Insurance Claims Development	The following table reconciles total outstanding liabilities, net of reinsurance to Benefits payable in the Consolidated Balance Sheet: As of December 31, (in thousands) 2024 2023 Short-duration healthcare costs payable, net of reinsurance $ 1,298,095 $ 908,875 Reinsurance recoverables 58,635 57,111 Total benefits payable $ 1,356,730 $ 965,986

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	The following table presents the interest expense indicating an effective interest rate of 7.61% over the term of the 2031 Notes: December 31, (in thousands) 2024 2023 Coupon interest expense $ 21,928 $ 22,112 Amortization of debt discount and issuance costs 778 778 Total interest expense $ 22,706 $ 22,890

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of stock option award activity	The following table summarizes the stock option award activity for the year ended December 31, 2024: Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Options Outstanding - December 31, 2023 26,378 $ 10.18 5.35 $ 15,700 Options granted 2 $ 18.48 Options exercised 7,810 $ 8.76 $ 71,687 Options canceled 626 $ 13.23 Options Outstanding - December 31, 2024 17,944 $ 10.69 4.87 $ 63,110 Options Exercisable at December 31, 2024 16,971 $ 10.87 4.68 $ 56,912
Summary of stock option valuation assumptions	The table below summarizes the assumptions used during the years ended December 31, 2024 and 2023. There were no stock options granted during the year ended December 31, 2022. December 31, 2024 2023 Term in years 5 6.02 - 6.14 Risk free rate of return 3.8% 3.5% - 4.7% Expected volatility 65.0% 58.2% - 59.4% Dividend yield — % — %
Summary of RSU activity	The following table summarizes RSU award activity for the year ended December 31, 2024: RSUs Number of Shares Weighted Average Grant Date Fair Value Outstanding RSUs at December 31, 2023 21,723 $ 7.06 RSUs granted 5,076 $ 14.71 RSUs vested 11,437 $ 8.18 RSUs canceled 2,230 $ 8.27 Outstanding RSUs at December 31, 2024 13,132 $ 8.83
Summary of PSU activity	The following table summarizes PSU award activity for the year ended December 31, 2024: PSUs Number of Shares Weighted Average Grant Date Fair Value Outstanding PSUs at December 31, 2023 9,305 $ 4.37 PSUs granted 857 $ 24.03 PSUs vested 1,851 $ 8.68 PSUs canceled 99 $ 24.03 Outstanding PSUs at December 31, 2024 8,212 $ 5.21
Summary of PSU valuation assumptions	December 31, 2024 December 31, 2023 Grant date stock price $ 18.09 $ 6.74 Term in years 3.0 3.0 Expected volatility 66.2 % 59.9 % Risk-free rate 4.6 % 3.6 % Dividend yield — % — %

REINSURANCE (Tables)

REINSURANCE (Tables)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Schedule of premiums earned	Year Ended December 31, (in thousands) 2024 2023 2022 Direct policy premiums $ 10,292,125 $ 6,418,872 $ 6,704,330 Assumed premiums 219,572 228,786 138,109 Risk adjustment transfers (1,526,448) (950,680) (1,507,919) Reinsurance premiums ceded (13,990) (10,909) (1,463,403) Premium $ 8,971,259 $ 5,686,069 $ 3,871,117 The following table reconciles total Medical expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, (in thousands) 2024 2023 2022 Direct claims incurred $ 7,278,267 $ 4,459,702 $ 4,428,000 Ceded reinsurance claims (159,132) (44,736) (1,290,349) Assumed reinsurance claims 213,454 227,058 143,147 Medical expenses $ 7,332,589 $ 4,642,024 $ 3,280,798 The Company records Selling, general and administrative ("SG&A") expenses net of reinsurance ceding commissions and assumed SG&A expenses. The following table reconciles total Selling, general and administrative expenses to the amount presented in the Consolidated Statements of Operations: Year Ended December 31, 2024 (in thousands) 2024 2023 2022 Selling, general and administrative expenses, gross $ 1,755,942 $ 1,424,763 $ 1,419,370 Reinsurance ceding commissions (377) 1,003 (161,946) Selling, general and administrative expenses $ 1,755,565 $ 1,425,766 $ 1,257,424 The composition of the Reinsurance recoverable balance on the Consolidated Balance Sheets is as follows: December 31, (in thousands) 2024 2023 Reinsurance premium and claim recoverables $ 288,878 $ 224,837 Reinsurance ceding commissions 6,996 7,054 Experience refunds on reinsurance agreements (4,338) 9,303 Reinsurance recoverable $ 291,537 $ 241,194

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	The components of the provision for income taxes are as follows for the periods indicated: Years Ended December 31, (in thousands) 2024 2023 2022 Current income tax expense (benefit): Federal $ 2,219 $ 3,222 $ (358) State 7,424 14 — Total current income tax expense (benefit) $ 9,643 $ 3,236 $ (358) Deferred income (benefit) tax: Federal $ 73 $ 58 $ (165) State (2,411) — — Total deferred tax (benefit) $ (2,338) $ 58 $ (165) Total income tax expense (benefit) $ 7,305 $ 3,294 $ (523)
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the tax provision at the U.S. federal statutory tax rate to the provision for income taxes and the effective tax rate follows for the periods indicated: Year Ended December 31, (in thousands, except percentages) 2024 2023 2022 Income (loss) before income taxes $ 33,426 $ (267,300) $ (610,075) Income tax benefit at statutory rate 21.00 % 21.00 % 21.00 % State taxes (net of federal income tax) 17.16 % (1.23) % 6.00 % Change in valuation allowance (10.88) % (11.08) % (23.27) % Stock-based compensation adjustment (99.52) % (1.65) % (1.92) % Non-deductible compensation 91.80 % (8.36) % (1.56) % Other permanent items 2.30 % 0.09 % (0.16) % Total income tax 21.86 % (1.23) % 0.09 %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred income tax assets and liabilities are as follows for the periods indicated: December 31, (in thousands) 2024 2023 Deferred Tax Assets: Net operating loss ("NOL") carryforwards $ 525,056 $ 548,147 Claims reserves 27,282 17,736 Deposit accounting 15,330 — Fixed assets and capitalized software 7,968 6,600 Accrued bonus 7,652 5,786 Allowance for credit loss 6,573 6,636 Unearned premium reserve 3,370 2,756 Stock option 2,824 2,396 Start-up costs 2,364 2,805 Unrealized losses 383 21 Premium deficiency reserves — 1,213 Other 5,932 6,568 Total deferred tax assets before valuation allowance 604,734 600,664 Valuation allowance 590,629 591,701 Total deferred tax assets, net of valuation allowance $ 14,105 $ 8,963 Deferred Tax Liabilities: Investments 5,131 2,553 Prepaid expenses 3,204 2,830 Unrealized gains 54 295 Other 2,676 2,581 Total deferred tax liabilities 11,065 8,259 Net deferred tax assets $ 3,040 $ 704

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Summary of Leases	The following table presents the lease-related balances within the balance sheet: December 31, (in thousands) Balance Sheet Classification 2024 2023 Operating Leases Right-of-use assets Other assets $ 57,153 $ 62,873 Lease liabilities, current Accounts payable and accrued liabilities $ 13,548 $ 14,175 Lease liabilities, noncurrent Other liabilities $ 60,651 $ 66,803 Additional Information: December 31, 2024 Weighted-average remaining lease term 6.2 years Weighted-average discount rate 10.65 %
Schedule of Operating Lease Liability Maturity	Future minimum rental payments under non-cancellable operating leases are estimated as follows: Year Ended December 31, (in thousands) 2025 $ 13,548 2026 16,445 2027 17,099 2028 17,168 2029 17,238 Thereafter 20,881 Total lease payments $ 102,379 Less: Imputed interest 28,180 Present value of lease liabilities $ 74,199

PROPERTY, EQUIPMENT AND CAPIT_2

PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The following table summarizes the balances of the Company’s property, equipment, and capitalized software: December 31, (in thousands) 2024 2023 Property, equipment, and capitalized software Software and hardware $ 148,260 $ 119,263 Leasehold improvements 26,386 25,301 Property and fixtures 6,248 5,443 Property, equipment, and capitalized software 180,894 150,007 Less: Accumulated depreciation and amortization (114,101) (88,077) Property, equipment, and capitalized software, net $ 66,793 $ 61,930

BUSINESS ARRANGEMENTS (Tables)

BUSINESS ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of variable interest entities	The following table presents the collective assets and liabilities of the Company's variable interest entities: As of December 31, (in thousands) 2024 2023 Assets $ 102,550 $ 90,683 Liabilities $ 63,114 $ 58,332

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents the revenue, significant expenses, and net income (loss) for the Company’s segment. As the Company operates and reports as a single segment, its measure of segment net income (loss) is the same as Net income (loss) attributable to Oscar Health, Inc. on the Consolidated Statements of Operations. Year Ended December 31, (in thousands) 2024 2023 2022 Total Revenue $ 9,177,564 $ 5,862,869 $ 3,963,638 Less: Medical expenses 7,332,589 4,642,024 3,280,798 Selling, general, and administrative expenses: Member acquisition and servicing costs (1) 747,627 540,135 679,464 Premium taxes, exchange fees, and other taxes and fees (2) 432,290 289,388 281,518 All other SG&A (3) 575,648 596,243 296,442 Total Selling, general, and administrative expenses 1,755,565 1,425,766 1,257,424 Depreciation and amortization 32,145 30,694 15,283 Earnings (loss) from operations 57,265 (235,615) (589,867) Interest expense 23,734 24,603 22,623 Other expense (income) 105 7,082 (2,415) Earnings (loss) before income taxes 33,426 (267,300) (610,075) Income tax expense (benefit) 7,305 3,294 (523) Net income (loss) attributable to noncontrolling interests 689 134 (3,277) Net income (loss) attributable to Oscar Health, Inc. $ 25,432 $ (270,728) $ (606,275) (1) Member acquisition and servicing costs include the Company’s expenses incurred to acquire, service, and fulfill obligations to members. (2) Premium taxes, exchange fees, and other taxes and fees represent non-income tax charges from federal and state governments, including but not limited to healthcare exchange user fees and premium taxes. (3) All other SG&A includes employee-related and administrative costs that are not member-based. Additionally, all other SG&A includes the net impact of quota share reinsurance accounted for under deposit accounting.

ORGANIZATION (Details)

ORGANIZATION (Details) member in Thousands	12 Months Ended
	Dec. 31, 2024 member segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments | segment	1
Number of members | member	1,680

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Property, Plant and Equipment [Line Items]
Number of reportable segments | segment	1
Benefits payable	$ 1,356,730	$ 965,986	$ 937,727	$ 513,582
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	2 years
Minimum | Internal-use software
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Maximum | Internal-use software
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Title Insurance Product Line
Property, Plant and Equipment [Line Items]
Benefits payable	$ 183,700	$ 241,100

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Allowance for Credit Losses on Risk Sharing Receivables (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Risk Adjustment Transfer Receivables, Allowance For Credit Loss [Roll Forward]
Premiums and other receivables, provision for credit losses, beginning of period	$ 31,600	$ 2,988
Provision for credit losses	(300)	28,612
Premiums and other receivables, provision for credit losses, end of period	$ 31,300	$ 31,600

REVENUE RECOGNITION -Schedule o

REVENUE RECOGNITION -Schedule of Premiums Earned (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Insurance [Abstract]
Direct policy premiums	$ 10,292,125	$ 6,418,872	$ 6,704,330
Assumed premiums	219,572	228,786	138,109
Risk adjustment transfers	(1,526,448)	(950,680)	(1,507,919)
Reinsurance premiums ceded	(13,990)	(10,909)	(1,463,403)
Premium	$ 8,971,259	$ 5,686,069	$ 3,871,117

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effects of Reinsurance [Line Items]
Direct policy premiums	$ 10,292,125	$ 6,418,872	$ 6,704,330
CMS
Effects of Reinsurance [Line Items]
Direct policy premiums	$ 9,512,300	$ 5,521,900	$ 5,730,100

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of basic and diluted earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net income (loss) attributable to Oscar Health, Inc.	$ 25,432	$ (270,728)	$ (606,275)
Effect of convertible senior notes	0	0	0
Net income (loss) available to Oscar Health, Inc. common shareholders	$ 25,432	$ (270,728)	$ (606,275)
Denominator:
Weighted average shares of common stock outstanding, basic (in shares)	240,386,000	221,655,000	212,475,000
Common stock equivalents (in shares)	25,467,000	0	0
Effect of convertible senior notes (in shares)	0	0	0
Weighted-average shares of common stock outstanding and potential dilutive common shares outstanding (in shares)	265,853,000	221,655,000	212,475,000
Net Earnings (Loss) per Share
Basic (in dollars per share)	$ 0.11	$ (1.22)	$ (2.85)
Diluted (in dollars per share)	$ 0.10	$ (1.22)	$ (2.85)

EARNINGS (LOSS) PER SHARE - S_2

EARNINGS (LOSS) PER SHARE - Schedule of antidilutive securities excluded from computation (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	38,247	94,058,000	91,442,000
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	1,249	26,378,000	28,729,000
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	346	21,723,000	17,596,000
Performance-based restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	0	9,305,000	8,465,000
Shares underlying convertible notes (Note 9)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	36,652	36,652,000	36,652,000

INVESTMENTS - Summary of invest

INVESTMENTS - Summary of investment income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Investment income	$ 186,526	$ 156,265	$ 28,632
Investment expense	(797)	(818)	(1,038)
Net investment income	185,729	155,447	27,594
Fixed maturity securities
Debt Securities, Available-for-sale [Line Items]
Investment income	82,085	59,965	10,713
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Investment income	98,618	90,152	22,121
Other
Debt Securities, Available-for-sale [Line Items]
Investment income	$ 5,823	$ 6,148	$ (4,202)

INVESTMENTS - Narrative (Detail

INVESTMENTS - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Accrued investment income	$ 19.8	$ 6.6

INVESTMENTS - Summary of inve_2

INVESTMENTS - Summary of investments (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 2,439,156	$ 1,053,859
Unrealized Gains	7,977	2,543
Unrealized Losses	(9,827)	(1,260)
Fair Value	2,437,306	1,055,142
Other	2,409
Total investments, amortized cost	2,441,565	1,053,859
Total investments, fair value	2,439,715	1,055,142
U.S. treasury and agency securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,946,759	802,288
Unrealized Gains	6,631	1,689
Unrealized Losses	(9,028)	(1,062)
Fair Value	1,944,362	802,915
Corporate notes
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	463,261	234,908
Unrealized Gains	1,346	854
Unrealized Losses	(799)	(198)
Fair Value	463,808	235,564
Certificate of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	29,136	16,663
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 29,136	$ 16,663

INVESTMENTS - Summary of inve_3

INVESTMENTS - Summary of investments in a gross unrealized loss position (Details) $ in Thousands	Dec. 31, 2024 USD ($) security	Dec. 31, 2023 USD ($) security
Less than 12 Months
Number of Securities | security	301	133
Fair Value	$ 877,287	$ 559,336
Gross Unrealized Losses	$ (9,802)	$ (1,161)
12 Months or Longer
Number of Securities | security	6	23
Fair Value	$ 47,748	$ 30,096
Gross Unrealized Losses	$ (25)	$ (99)
U.S. treasury and agency securities
Less than 12 Months
Number of Securities | security	191	69
Fair Value	$ 730,938	$ 480,312
Gross Unrealized Losses	$ (9,003)	$ (995)
12 Months or Longer
Number of Securities | security	6	4
Fair Value	$ 47,748	$ 24,551
Gross Unrealized Losses	$ (25)	$ (67)
Corporate notes
Less than 12 Months
Number of Securities | security	110	64
Fair Value	$ 146,349	$ 79,024
Gross Unrealized Losses	$ (799)	$ (166)
12 Months or Longer
Number of Securities | security	0	19
Fair Value	$ 0	$ 5,545
Gross Unrealized Losses	$ 0	$ (32)

INVESTMENTS - Summary of contra

INVESTMENTS - Summary of contractual maturities of available-for-sale securities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Amortized Cost
Due in one year or less	$ 623,465	$ 690,694
Due after one year through five years	1,815,691	363,165
Amortized Cost	2,439,156	1,053,859
Fair Value
Due in one year or less	624,461	689,833
Due after one year through five years	1,812,845	365,309
Fair Value	$ 2,437,306	$ 1,055,142

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 2,437,306	$ 1,055,142
U.S. treasury and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	1,944,362	802,915
Corporate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	463,808	235,564
Certificate of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	29,136	16,663
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	95,331	434,330
Total assets	2,539,583	1,497,686
Recurring | U.S. treasury and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	1,944,362	802,915
Recurring | Corporate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	463,808	235,564
Recurring | Certificate of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	29,136	16,663
Restricted investments	0	2,478
Recurring | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	6,946	5,736
(Level 1) | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	95,331	434,330
Total assets	95,331	434,330
(Level 1) | Recurring | U.S. treasury and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
(Level 1) | Recurring | Corporate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
(Level 1) | Recurring | Certificate of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Restricted investments	0	0
(Level 1) | Recurring | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	0	0
(Level 2) | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total assets	2,444,252	1,063,356
(Level 2) | Recurring | U.S. treasury and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	1,944,362	802,915
(Level 2) | Recurring | Corporate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	463,808	235,564
(Level 2) | Recurring | Certificate of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	29,136	16,663
Restricted investments	0	2,478
(Level 2) | Recurring | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	6,946	5,736
(Level 3) | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total assets	0	0
(Level 3) | Recurring | U.S. treasury and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
(Level 3) | Recurring | Corporate notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
(Level 3) | Recurring | Certificate of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Restricted investments	0	0
(Level 3) | Recurring | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	$ 0	$ 0

RESTRICTED CASH AND RESTRICTE_3

RESTRICTED CASH AND RESTRICTED DEPOSITS (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Restricted cash and cash equivalents	$ 23,932	$ 21,656
Restricted investments	6,946	8,214
Restricted deposits	$ 30,878	$ 29,870

BENEFITS PAYABLE - Summary of B

BENEFITS PAYABLE - Summary of Benefits Payable And Claims Adjustment Expenses ("CAE") Payable Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Benefits payable, beginning of period	$ 965,986	$ 937,727	$ 513,582
CAE payable, beginning of the period	13,192	12,712	9,101
Benefits and CAE payable, beginning of period	1,374,971	979,178	950,439	$ 522,683
Less: Reinsurance recoverable	57,111	277,944	159,180
Benefits payable, net reinsurance recoverable, beginning of period	908,875	659,783	354,402
Benefits and CAE payable, net, beginning of period	922,067	672,495	363,503
Benefits Payable
Current year	7,497,259	4,622,263	3,279,460
Prior years	(164,670)	19,761	1,338
Claims incurred	7,332,589	4,642,024	3,280,798
Unallocated Claims Adjustment Expense
Current year	108,492	105,565	117,541
Prior years	0	0	0
Claims adjustment expense	108,492	105,565	117,541
Total
Current year	7,605,751	4,727,828	3,397,001
Prior years	(164,670)	19,761	1,338
Total claims incurred and CAE, net	7,441,081	4,747,589	3,398,339
Benefits Payable
Current year	6,349,624	3,840,009	2,726,912
Prior years	593,745	552,923	248,505
Claims paid	6,943,369	4,392,932	2,975,417
Unallocated Claims Adjustment Expense
Current year	92,758	94,807	106,871
Prior years	10,685	10,278	7,059
CAE paid	103,443	105,085	113,930
Total
Current year	6,442,382	3,934,816	2,833,783
Prior years	604,430	563,201	255,564
Total claims and CAE paid, net	7,046,812	4,498,017	3,089,347
Benefits payable, net reinsurance recoverable, end of period	1,298,095	908,875	659,783
CAE payable, end of the period	18,241	13,192	12,712
Benefits and CAE payable, net, end of period	1,316,336	922,067	672,495
Add: Reinsurance recoverable	58,635	57,111	277,944
Benefits payable, end of period	1,356,730	965,986	937,727
Benefits and CAE payable, end of period	$ 1,374,971	$ 979,178	$ 950,439

BENEFITS PAYABLE - Summary of I

BENEFITS PAYABLE - Summary of Insurance Claims Development (Details) claim in Thousands, $ in Thousands	Dec. 31, 2024 USD ($) claim	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Claims Development [Line Items]
Claims incurred	$ 15,277,898
Claims paid	14,002,686
All outstanding liabilities prior to 2022, net of reinsurance	22,883
Total benefits payable, net of reinsurance	1,298,095	$ 908,875
2022
Claims Development [Line Items]
Claims incurred	3,310,967	3,314,332	$ 3,279,461
Incurred but not reported (IBNR)	$ 31,889
Cumulative number of reported claims | claim	12,725
Claims paid	$ 3,279,078	3,223,917	$ 2,726,912
2023
Claims Development [Line Items]
Claims incurred	4,469,672	4,622,263
Incurred but not reported (IBNR)	$ 95,688
Cumulative number of reported claims | claim	11,526
Claims paid	$ 4,373,984	$ 3,840,009
2024
Claims Development [Line Items]
Claims incurred	7,497,259
Incurred but not reported (IBNR)	$ 1,147,635
Cumulative number of reported claims | claim	17,917
Claims paid	$ 6,349,624

BENEFITS PAYABLE - Reconciliati

BENEFITS PAYABLE - Reconciliation of Claims Development to Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Insurance [Abstract]
Short-duration healthcare costs payable, net of reinsurance	$ 1,298,095	$ 908,875
Reinsurance recoverables	58,635	57,111	$ 277,944	$ 159,180
Benefits payable	$ 1,356,730	$ 965,986	$ 937,727	$ 513,582

DEBT - Narrative (Details)

DEBT - Narrative (Details)		1 Months Ended	3 Months Ended
	Feb. 21, 2021 USD ($)	Feb. 28, 2022 USD ($) tradingDay $ / shares	Dec. 31, 2024 USD ($) tradingDay $ / shares	Dec. 28, 2023 USD ($)
7.25% convertible senior notes due 2031 | Convertible debt
Debt Instrument [Line Items]
Aggregate principal amount		$ 305,000,000
Stated interest rate		7.25%
Conversion ratio		0.1201721
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares		$ 8.32	$ 8.32
Debt instrument, convertible, threshold percentage of stock price trigger		200%	130%
Debt instrument, convertible, threshold trading days | tradingDay		20	20
Debt instrument, convertible, threshold consecutive trading days | tradingDay		30	30
Long-term debt			$ 299,600,000
Unamortized debt discount and debt issuance costs			5,400,000
Long-term debt, fair value			$ 539,800,000
Debt instrument, interest rate, effective percentage			7.61%
Revolving Credit Agreement | Line of credit | Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 115,000,000
Commitment fee	0.50%
Borrowing capacity, increase limit	$ 50,000,000
Line of credit outstanding			$ 0
Revolving Credit Agreement | Line of credit | Revolving credit facility | Adjusted Term Secured Overnight Financing Rate
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%
Variable rate, floor	1%
Revolving Credit Agreement | Line of credit | Revolving credit facility | Alternative Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	3.50%
Revolving Credit Agreement | Line of credit | Revolving credit facility | Fed funds effective rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Revolving Credit Agreement | Line of credit | Revolving credit facility | One Month Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate	1%

DEBT - Schedule of debt interes

DEBT - Schedule of debt interest expense (Details) - 7.25% convertible senior notes due 2031 - Convertible debt - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Coupon interest expense	$ 21,928	$ 22,112
Amortization of debt discount and issuance costs	778	778
Total interest expense	$ 22,706	$ 22,890

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Mar. 28, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 119,000	$ 166,800	$ 112,300
Share-based payment arrangement, amount capitalized		$ 9,100	$ 7,100	$ 0
Options granted, weighted average grant date fair value (in dollars per share)		$ 10.65	$ 3.74
Options granted (in shares)		2,000		0
Options exercised, aggregate intrinsic value		$ 71,687	$ 8,500	$ 1,000
Unrecognized compensation expense, options		$ 3,400
Accelerated stock-based compensation expense	$ 46,300
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage of target amount		200%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 8,700	12,000	21,500
Maximum contractual term		10 years
Award vesting period		4 years
Unrecognized compensation expense, period for recognition		2 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 95,000	90,000	65,500
Unrecognized compensation expense, period for recognition		1 year 7 months 6 days
Fair value of restricted stock units vested in the period		$ 93,600	89,700
Unrecognized compensation expense		$ 101,200
Granted (in shares)		5,076,000
Canceled (in shares)		2,230,000
RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		1 year
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		4 years
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 15,300	$ 64,900	$ 25,300
Award vesting period		3 years
Unrecognized compensation expense, period for recognition		1 year 8 months 12 days
Unrecognized compensation expense		$ 23,900
Granted (in shares)		857,000		0
Canceled (in shares)		99,000
PSUs | Founder, Mario Schlosser
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Canceled (in shares)	4,229,853
PSUs | Founder, Joshua Kushner
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Canceled (in shares)	2,114,926
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage of target amount		0%
2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		49,200,000
Number of shares available for issuance		7,200,000
2022 Inducement Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		18,300,000
Number of shares available for issuance		5,800,000
Additional shares authorized (in shares)	13,300,000

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Option Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of Options (in thousands)
Beginning balance (in shares)	26,378,000
Options granted (in shares)	2,000		0
Options exercised (in shares)	7,810,000
Options canceled (in shares)	626,000
Ending balance (in shares)	17,944,000	26,378,000
Options exercisable (in shares)	16,971,000
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 10.18
Options granted (in dollars per share)	18.48
Options exercised (in dollars per share)	8.76
Options canceled (in dollars per share)	13.23
Ending balance (in dollars per share)	10.69	$ 10.18
Options exercisable (in dollars per share)	$ 10.87
Weighted Average Remaining Contractual Life (in years)
Options outstanding, weighted average contractual life	4 years 10 months 13 days	5 years 4 months 6 days
Options exercisable, weighted average contractual life	4 years 8 months 4 days
Aggregate Intrinsic Value (in thousands)
Beginning balance, aggregate intrinsic value	$ 15,700
Options exercised, aggregate intrinsic value	71,687	$ 8,500	$ 1,000
Ending balance, aggregate intrinsic value	63,110	$ 15,700
Options exercisable, aggregate intrinsic value	$ 56,912

STOCK-BASED COMPENSATION - Su_2

STOCK-BASED COMPENSATION - Summary of Valuation Stock Option Assumptions (Details) - Stock options	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years	5 years
Risk free rate of return	3.80%
Risk free rate of return, minimum		3.50%
Risk free rate of return, maximum		4.70%
Expected volatility	65%
Expected volatility, minimum		58.20%
Expected volatility, maximum		59.40%
Dividend yield	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years		6 years 7 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years		6 years 1 month 20 days

STOCK-BASED COMPENSATION - Su_3

STOCK-BASED COMPENSATION - Summary of RSU Activity (Details) - RSUs shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Number of Shares (in thousands)
Outstanding, beginning balance (in shares) | shares	21,723
Granted (in shares) | shares	5,076
Vested (in shares) | shares	11,437
Canceled (in shares) | shares	2,230
Outstanding, ending balance (in shares) | shares	13,132
Weighted Average Grant Date Fair Value
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 7.06
Granted (in dollars per share) | $ / shares	14.71
Vested (in dollars per share) | $ / shares	8.18
Canceled (in dollars per share) | $ / shares	8.27
Outstanding, ending balance (in dollars per share) | $ / shares	$ 8.83

STOCK-BASED COMPENSATION - Su_4

STOCK-BASED COMPENSATION - Summary of PSU Activity (Details) - PSUs - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2022
Number of Shares (in thousands)
Outstanding, beginning balance (in shares)	9,305,000
Granted (in shares)	857,000	0
Vested (in shares)	1,851,000
Canceled (in shares)	(99,000)
Outstanding, ending balance (in shares)	8,212,000
Weighted Average Grant Date Fair Value
Outstanding, beginning balance (in dollars per share)	$ 4.37
Granted (in dollars per share)	24.03
Vested (in dollars per share)	8.68
Canceled (in dollars per share)	24.03
Outstanding, ending balance (in dollars per share)	$ 5.21

STOCK-BASED COMPENSATION - Su_5

STOCK-BASED COMPENSATION - Summary of PSU Valuation Assumptions (Details) - PSUs - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date stock price (in dollars per share)	$ 18.09	$ 6.74
Term in years	3 years	3 years
Expected volatility	66.20%	59.90%
Risk-free rate	4.60%	3.60%
Dividend yield	0%	0%

REINSURANCE - Narrative (Detail

REINSURANCE - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Insurance [Abstract]
Reinsurance, deposit liability	$ 13.6	$ 7
Reinsurance premiums ceded, percentage	53%	45%	18%

REINSURANCE - Reinsurance Arran

REINSURANCE - Reinsurance Arrangements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Policyholder Benefits and Claims Incurred, Net [Abstract]
Direct claims incurred	$ 7,278,267	$ 4,459,702	$ 4,428,000
Ceded reinsurance claims	(159,132)	(44,736)	(1,290,349)
Assumed reinsurance claims	213,454	227,058	143,147
Medical expenses	7,332,589	4,642,024	3,280,798
Other Insurance Cost, Net [Abstract]
Selling, general and administrative expenses, gross	1,755,942	1,424,763	1,419,370
Reinsurance ceding commissions	(377)	1,003	(161,946)
Selling, general and administrative expenses	1,755,565	1,425,766	$ 1,257,424
Reinsurance Recoverables, Including Reinsurance Premium Paid [Abstract]
Reinsurance premium and claim recoverables	288,878	224,837
Reinsurance ceding commissions	6,996	7,054
Experience refunds on reinsurance agreements	(4,338)	9,303
Reinsurance recoverable	$ 291,537	$ 241,194

INCOME TAXES - Schedule of Comp

INCOME TAXES - Schedule of Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current income tax expense (benefit):
Federal	$ 2,219	$ 3,222	$ (358)
State	7,424	14	0
Total current income tax expense (benefit)	9,643	3,236	(358)
Deferred income (benefit) tax:
Federal	73	58	(165)
State	(2,411)	0	0
Total deferred tax (benefit)	(2,338)	58	(165)
Total income tax expense (benefit)	$ 7,305	$ 3,294	$ (523)

INCOME TAXES - Schedule of Effe

INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 33,426	$ (267,300)	$ (610,075)
Percent
Income tax benefit at statutory rate	21%	21%	21%
State taxes (net of federal income tax)	17.16%	(1.23%)	6%
Change in valuation allowance	(10.88%)	(11.08%)	(23.27%)
Stock-based compensation adjustment	(99.52%)	(1.65%)	(1.92%)
Non-deductible compensation	91.80%	(8.36%)	(1.56%)
Other permanent items	2.30%	0.09%	(0.16%)
Total income tax	21.86%	(1.23%)	0.09%

INCOME TAXES - Schedule of Defe

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred Tax Assets:
Net operating loss ("NOL") carryforwards	$ 525,056	$ 548,147
Claims reserves	27,282	17,736
Deposit accounting	15,330	0
Fixed assets and capitalized software	7,968	6,600
Accrued bonus	7,652	5,786
Allowance for credit loss	6,573	6,636
Unearned premium reserve	3,370	2,756
Stock option	2,824	2,396
Start-up costs	2,364	2,805
Unrealized losses	383	21
Premium deficiency reserves	0	1,213
Other	5,932	6,568
Total deferred tax assets before valuation allowance	604,734	600,664
Valuation allowance	590,629	591,701
Total deferred tax assets, net of valuation allowance	14,105	8,963
Deferred Tax Liabilities:
Investments	5,131	2,553
Prepaid expenses	3,204	2,830
Unrealized gains	54	295
Other	2,676	2,581
Total deferred tax liabilities	11,065	8,259
Net deferred tax assets	$ 3,040	$ 704

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 590,629,000	$ 591,701,000
Unrecognized tax benefits	0	0	$ 0
Unrecognized tax benefits, penalties and interest expense	0	$ 0	$ 0
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	2,156,800,000
Net operating loss carryforwards, subject to expiration	1,249,000,000
Net operating loss carryforwards, not subject to expiration	907,800,000
State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, group filings	1,001,500,000
Operating loss carryforwards, standalone filings	$ 298,900,000

LEASES - Summary of Lease-relat

LEASES - Summary of Lease-related Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Operating Leases
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Right-of-use assets	$ 57,153	$ 62,873
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable and other liabilities	Accounts payable and other liabilities
Lease liabilities, current	$ 13,548	$ 14,175
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Lease liabilities, noncurrent	$ 60,651	$ 66,803

LEASES - Narrative (Details)

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Lease costs	$ 14.5	$ 14.7	$ 14.8
Operating lease payments	$ 14.2	$ 14

LEASES - Schedule of Operating

LEASES - Schedule of Operating Lease Liability Maturity (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 13,548
2026	16,445
2027	17,099
2028	17,168
2029	17,238
Thereafter	20,881
Total lease payments	102,379
Less: Imputed interest	28,180
Present value of lease liabilities	$ 74,199

LEASES - Additional Information

LEASES - Additional Information (Details)	Dec. 31, 2024
Leases [Abstract]
Weighted-average remaining lease term	6 years 2 months 12 days
Weighted-average discount rate	10.65%

PROPERTY, EQUIPMENT AND CAPIT_3

PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, equipment, and capitalized software	$ 180,894	$ 150,007
Less: Accumulated depreciation and amortization	(114,101)	(88,077)
Property, equipment, and capitalized software, net	66,793	61,930
Software and hardware
Property, Plant and Equipment [Line Items]
Property, equipment, and capitalized software	148,260	119,263
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, equipment, and capitalized software	26,386	25,301
Property and fixtures
Property, Plant and Equipment [Line Items]
Property, equipment, and capitalized software	$ 6,248	$ 5,443

PROPERTY, EQUIPMENT AND CAPIT_4

PROPERTY, EQUIPMENT AND CAPITALIZED SOFTWARE- Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 32,145	$ 30,694	$ 15,283

BUSINESS ARRANGEMENTS - Variabl

BUSINESS ARRANGEMENTS - Variable interest entities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Assets	$ 4,840,496	$ 3,601,480
Liabilities	3,824,071	2,795,363
Primary Beneficiary
Variable Interest Entity [Line Items]
Assets	102,550	90,683
Liabilities	$ 63,114	$ 58,332

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)	Dec. 31, 2024 vote
Class A
Subsidiary, Sale of Stock [Line Items]
Voting rights, number of votes	1
Common stock, conversion ratio	1
Class B
Subsidiary, Sale of Stock [Line Items]
Voting rights, number of votes	20

STATUTORY REGULATIONS (Details)

STATUTORY REGULATIONS (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Insurance [Abstract]
Combined statutory capital and surplus	$ 1,242.7	$ 800.6

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting [Abstract]
Total Revenue	$ 9,177,564	$ 5,862,869	$ 3,963,638
Medical	7,332,589	4,642,024	3,280,798
Member acquisition and servicing costs	747,627	540,135	679,464
Premium taxes, exchange fees, and other taxes and fees	432,290	289,388	281,518
All other SG&A	575,648	596,243	296,442
Selling, general and administrative expenses	1,755,565	1,425,766	1,257,424
Depreciation and amortization	32,145	30,694	15,283
Earnings (loss) from operations	57,265	(235,615)	(589,867)
Interest expense	23,734	24,603	22,623
Other expense (income)	105	7,082	(2,415)
Earnings (loss) before income taxes	33,426	(267,300)	(610,075)
Income tax expense (benefit)	7,305	3,294	(523)
Net income (loss) attributable to noncontrolling interests	689	134	(3,277)
Net income (loss) attributable to Oscar Health, Inc.	$ 25,432	$ (270,728)	$ (606,275)

SCHEDULE I - CONDENSED FINANC_2

SCHEDULE I - CONDENSED FINANCIAL INFORMATION - Condensed Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 1,527,186	$ 1,870,315	$ 1,558,595
Other assets	21,320	6,564
Total assets	4,840,496	3,601,480
Liabilities and Stockholders' Equity
Long-term debt	299,555	298,777
Other liabilities	61,282	67,574
Total liabilities	3,824,071	2,795,363
Commitments and contingencies (Note 19)
Stockholders' Equity
Treasury stock (315 thousand shares as of December 31, 2024 and 2023)	(2,923)	(2,923)
Additional paid-in capital	3,869,617	3,682,294
Accumulated deficit	(2,851,283)	(2,876,715)
Accumulated other comprehensive income (loss)	(1,827)	1,309
Total Oscar Health, Inc. stockholders’ equity	1,013,586	803,967
Total liabilities and stockholders' equity	4,840,496	3,601,480
Class A
Stockholders' Equity
Common stock	2	2
Class B
Stockholders' Equity
Common stock	0	0
Parent
Assets
Cash and cash equivalents	97,384	171,940
Restricted deposits and investments	9,086	23,589
Investments in and advances to subsidiaries	1,207,848	925,926
Other assets	11,801	5,990
Total assets	1,326,119	1,127,445
Liabilities and Stockholders' Equity
Long-term debt	299,555	298,777
Other liabilities	12,978	24,701
Total liabilities	312,533	323,478
Commitments and contingencies (Note 19)
Stockholders' Equity
Treasury stock (315 thousand shares as of December 31, 2024 and 2023)	(2,923)	(2,923)
Additional paid-in capital	3,869,617	3,682,294
Accumulated deficit	(2,851,283)	(2,876,715)
Accumulated other comprehensive income (loss)	(1,827)	1,309
Total Oscar Health, Inc. stockholders’ equity	1,013,586	803,967
Total liabilities and stockholders' equity	1,326,119	1,127,445
Parent | Class A
Stockholders' Equity
Common stock	2	2
Parent | Class B
Stockholders' Equity
Common stock	$ 0	$ 0

SCHEDULE I - CONDENSED FINANC_3

SCHEDULE I - CONDENSED FINANCIAL INFORMATION - Condensed Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue
Investment income and other revenue	$ 185,729	$ 155,447	$ 27,594
Total revenue	9,177,564	5,862,869	3,963,638
Operating Expenses
Depreciation and amortization	32,145	30,694	15,283
Interest expense	23,734	24,603	22,623
Earnings (loss) before income taxes	33,426	(267,300)	(610,075)
Income tax (benefit) provision	7,305	3,294	(523)
Net income (loss) attributable to Oscar Health, Inc.	25,432	(270,728)	(606,275)
Parent
Revenue
Investment income and other revenue	16,714	20,253	8,274
Total revenue	16,714	20,253	8,274
Operating Expenses
Depreciation and amortization	118,566	106,387	60,130
Interest expense	23,697	24,577	22,583
Other expenses (income)	110	7,081	(2,415)
Earnings (loss) before income taxes	(125,659)	(117,792)	(72,024)
Income tax (benefit) provision	(34,777)	(7,870)	2,703
Loss before equity in net loss of subsidiaries	(90,882)	(109,922)	(74,727)
Equity in net income (loss) of subsidiaries	116,314	(160,806)	(531,548)
Net income (loss) attributable to Oscar Health, Inc.	$ 25,432	$ (270,728)	$ (606,275)

SCHEDULE I - CONDENSED FINANC_4

SCHEDULE I - CONDENSED FINANCIAL INFORMATION - Condensed Statements of Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Condensed Statement of Income Captions [Line Items]
Net income (loss) attributable to Oscar Health, Inc.	$ 25,432	$ (270,728)	$ (606,275)
Other comprehensive income (loss), net of tax:
Comprehensive income (loss) attributable to Oscar Health, Inc.	22,296	(259,704)	(612,319)
Parent
Condensed Statement of Income Captions [Line Items]
Net income (loss) attributable to Oscar Health, Inc.	25,432	(270,728)	(606,275)
Other comprehensive income (loss), net of tax:
Net unrealized gains (losses) on securities available for sale	(3,136)	11,024	(6,044)
Comprehensive income (loss) attributable to Oscar Health, Inc.	$ 22,296	$ (259,704)	$ (612,319)

SCHEDULE I - CONDENSED FINANC_5

SCHEDULE I - CONDENSED FINANCIAL INFORMATION - Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	$ 978,193	$ (272,159)	$ 380,349
Cash Flows from Investing Activities:
Purchase of fixed maturity securities	(2,133,510)	(836,982)	(1,192,706)
Sale of investments	25,250	31,857	360,616
Maturity of investments	744,794	1,410,166	633,467
Net cash (used in) provided by investing activities	(1,387,434)	577,187	(226,519)
Cash Flows from Financing Activities:
Proceeds from long-term debt	0	0	305,000
Proceeds from joint venture contribution	0	2,490	1,846
Proceeds from exercise of stock options	68,388	3,956	1,299
Payments of debt issuance costs	0	0	(7,035)
Net cash provided by financing activities	68,388	6,446	301,110
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(340,853)	311,474	454,940
Cash, cash equivalents, restricted cash and cash equivalents—beginning of period	1,891,971	1,580,497	1,125,557
Cash, cash equivalents, restricted cash and cash equivalents—end of period	1,551,118	1,891,971	1,580,497
Parent
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	2,103	9,055	(3,957)
Cash Flows from Investing Activities:
Investments in subsidiaries	(159,628)	(149,025)	(652,008)
Purchase of investments	(2,409)	0	0
Purchase of fixed maturity securities	0	0	(138,919)
Sale of investments	0	(15,775)	295,316
Maturity of investments	16,990	306,511	155,578
Net cash (used in) provided by investing activities	(145,047)	141,711	(340,033)
Cash Flows from Financing Activities:
Proceeds from long-term debt	0	0	305,000
Proceeds from joint venture contribution	0	2,490	1,846
Proceeds from exercise of stock options	68,388	3,956	1,299
Payments of debt issuance costs	0	0	(7,035)
Net cash provided by financing activities	68,388	6,446	301,110
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(74,556)	157,212	(42,880)
Cash, cash equivalents, restricted cash and cash equivalents—beginning of period	171,940	14,728	57,608
Cash, cash equivalents, restricted cash and cash equivalents—end of period	$ 97,384	$ 171,940	$ 14,728